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Abstract 
  
 Respiratory syncytial virus (RSV) causes a common infection that is associated 
with a range of respiratory illnesses from common cold-like symptoms to serious lower 
respiratory tract illnesses such as pneumonia and bronchiolitis.  RSV is the single most 
important cause of serious lower respiratory tract illness in children < 1 year of age.  Host 
innate and acquired immune responses activated following RSV infection have been 
suspected as contributing to RSV disease.  Toll-like receptors (TLRs) activate innate and 
acquired immunity and are candidates for playing key roles in the host immune response 
to RSV.  Leukocytes express TLRs including TLR2, TLR6, TLR3, TLR4, and TLR7 that 
can potentially interact with RSV and promote immune responses following infection.  
Using knockout mice, we have demonstrated that TLR2 and TLR6 signaling in 
leukocytes can activate innate immunity against RSV by promoting TNF-!, IL-6, CCL2 
(MCP-1), and CCL5 (RANTES) production.  As previously noted, TLR4 also contributed 
to cytokine activation (71, 90).  Furthermore, we demonstrated that signals generated 
following TLR2 and TLR6 activation were important for controlling viral replication in 
vivo.  Additionally, TLR2 interactions with RSV promoted neutrophil migration and 
dendritic cell activation within the lung.  Collectively, these studies indicate that TLR2 is 
involved in RSV recognition and subsequent innate immune activation and may play a 
role in modulating acquired immune responses through DCs.   
 Despite the fact that RSV is the single most important cause of infant upper 
respiratory tract disease, there are no licensed vaccines available to prevent RSV disease. 
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We have developed a virus-like particle (VLP) vaccine candidate for RSV.  The VLP is 
composed of the NP and M proteins of Newcastle disease virus (NDV) and a chimera 
protein containing the cytoplasmic and transmembrane domains of the NDV HN protein 
and the ectodomain of the human RSV G protein (H/G).   BALB/c mice immunized with 
10 or 40 !g total VLP-H/G protein by intraperitoneal or intramuscular inoculation 
stimulated antibody responses to G protein as good as or better than comparable amounts 
of UV-inactivated RSV.   Furthermore, VLP-H/G induced robust CTL responses in 
vaccinated animals.  Immunization with two or even a single dose of these particles 
resulted in the complete protection of BALB/c mice from RSV replication in the lungs.  
Upon RSV challenge of VLP-H/G immunized mice, no enhanced pathology in the lungs 
was observed, although lungs of mice immunized in parallel with formalin-inactivated 
RSV (FI-RSV) showed the significant pathology that has been previously observed with 
FI-RSV vaccination.   Thus, the VLP-H/G candidate vaccine was immunogenic in 
BALB/c mice and prevented replication of RSV in murine lungs with no evidence of 
immunopathology.  These data support further development of virus-like particle vaccine 
candidates for RSV. 
 
 
 
 
 
 
  
ix 
Table of Contents 
Approval Page...................................................................................................... i 
Copyright Information........................................................................................ iii 
Acknowledgements ............................................................................................ iv 
Abstract............................................................................................................. vii 
Table of Contents ............................................................................................... ix 
List of Figures ................................................................................................... xii 
List of Tables .................................................................................................... xv 
List of Abbreviations........................................................................................ xvi 
Chapter I   
Introduction......................................................................................................... 1 
RSV the virus...................................................................................................... 1 
RSV the pathogen................................................................................................ 6 
RSV pathogenesis ............................................................................................... 8 
Role of innate immunity in recognizing RSV....................................................... 9 
Linking innate and adaptive immune responses against RSV............................. 15 
Host adaptive immune response to RSV............................................................ 16 
Host factors that contribute to disease susceptibility .......................................... 19 
Virus factors that contribute to disease susceptibility......................................... 21 
Animal models used to study RSV .................................................................... 23 
Developing a novel vaccine strategy for RSV.................................................... 25 
Previous attempts to develop RSV vaccine ........................................................ 25 
  
x 
Virus-like particle as vaccine candidates............................................................ 26 
Virus-like particles as candidate vaccines for RSV............................................ 27 
Research Objectives .......................................................................................... 27 
Chapter II  TLR2 recognizes RSV 
Introduction....................................................................................................... 29 
Results .............................................................................................................. 30 
Discussion......................................................................................................... 46 
Chapter III  TLR2 signaling activates innate immune responses against RSV 
Introduction....................................................................................................... 52 
Results .............................................................................................................. 53 
Discussion......................................................................................................... 60 
Chapter IV  Virus-like Particles (VLPs) expressing RSV G glycoprotein can be used as a 
safe and efficacious vaccine in BALB/c mice 
Preface .............................................................................................................. 64 
Introduction....................................................................................................... 65 
Results .............................................................................................................. 67 
Discussion......................................................................................................... 98 
Chapter V  Conclusions and Future Directions ................................................ 107 
Chapter VI  Materials and Methods ................................................................. 111 
Chapters II and III ........................................................................................... 111 
Chapters III and IV.......................................................................................... 118 
Appendix I  Upregulation of Foxp3 Expression in Mouse and Human Treg                       
Is IL-2/STAT5 Dependent; Implications for the NOD STAT5B Mutation in  
  
xi 
Diabetes Pathogenesis...................................................................................... 129 
  
 
References....................................................................................................... 136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
xii 
List of Figures 
 
Chapter I 
Figure  1.1  RSV structure and genome................................................................ 2 
Figure  1.2  TLRs are PRRs that recognize invading pathogens  
by their PAMP .................................................................................................. 10 
 
Figure  1.3  TLR/pathogen interactions induce innate signaling responses  
within host cells ................................................................................................ 13 
 
Figure  1.4  Dendritic cells (DCs) link innate and adaptive immune  
Responses.......................................................................................................... 17 
 
Chapter II 
 
Figure  2.1  C57BL6/J PECs are more responsive to TLR ligands  
and RSV than BALB/c PECs............................................................................. 33 
 
Figure  2.2  C57BL6/J PECs express more surface TLR2 than  
BALB/c PECs after RSV stimulation................................................................. 35 
 
Figure  2.3  TLR2 associates with RSV ............................................................. 37 
 
Figure  2.4 RSV replication is not required to elicit TLR2 responses ................. 38 
 
Figure  2.5 Sucrose-purified RSV stimulates PECs similar to Vero cell-  
propagated RSV ................................................................................................ 39 
 
Figure  2.6 TLR2 dimer partner TLR6, but not dimer partner TLR1,  
recognizes RSV................................................................................................. 40  
 
Figure  2.7  TLR2 and TLR6 mediate inflammatory cytokine production  
in response to RSV............................................................................................ 42 
 
Figure  2.8  TLR2 and TLR6 mediate chemokine production in  
response to RSV................................................................................................ 43 
 
Figure  2.9  TLR2 and TLR6 are not involved in type I interferon  
production following RSV recognition .............................................................. 45 
 
  
xiii 
Chapter III 
 
Figure  3.1  RSV replication in TLR KO mice................................................... 54 
 
Figure  3.2  TLR2 signaling promotes CCL2 production in vivo ........................ 56 
 
Figure  3.3  TLR2 signals promote neutrophil influx following  
RSV infection.................................................................................................... 58 
 
Figure  3.4  TLR2 signals promote DC maturation in  
response to RSV................................................................................................ 59 
 
Chapter IV 
 
Figure  4.1  Producing VLPs in vitro ................................................................. 66 
 
Figure  4.2  Constructing H/G chimera protein .................................................. 68 
 
Figure  4.3  Expressing H/G chimera protein in vitro ......................................... 69 
 
Figure  4.4  Incorporating H/G chimera protein into ND-VLP ........................... 71 
 
Figure  4.5  Quantifying ND-VLPs expressing H/G protein chimera.................. 72 
 
Figure  4.6  VLP-H/G quantification for vaccine dosing .................................... 75 
 
Figure  4.7  Antibody responses to RSV G protein in vaccinated mice 
(COS7 G target antigen) .................................................................................... 76 
 
Figure 4.8 Antibody responses to RSV G following vaccination (I.P.)  
(HEK 293T G protein and purified RSV G protein target antigen)..................... 77 
  
Figure  4.9 VLP-H/G vaccination (I.P.) protects mice from RSV  
replication in lungs ............................................................................................ 79 
 
Figure  4.10  Antibody responses to RSV G following vaccination (I.M.)  
(293T G protein target antigen).......................................................................... 80 
 
Figure  4.11  CTL responses following VLP-H/G vaccination (I.M.) ................. 82  
 
Figure  4.12  VLP-H/G vaccination protects from RSV replication  
in mouse lungs .................................................................................................. 84 
 
Figure  4.13  Normal Mouse lung anatomy........................................................ 86 
  
xiv 
Figure  4.14  FI-RSV vaccination enhanced pathology in  
mouse lung........................................................................................................ 88  
 
Figure  4.15  Mouse lung morphology after VLP-H/G  
Vaccination ....................................................................................................... 90 
 
Figure  4.16  Statistical analysis of inflammation around mouse airways  
after VLP-H/G vaccination................................................................................ 92  
 
Figure  4.17 Statistical analysis of inflammation around mouse blood  
vessels after VLP-H/G vaccination .................................................................... 93 
 
Figure  4.18 Statistical analysis of inflammation around mouse interstitial  
spaces after VLP-H/G vaccination..................................................................... 94 
 
Figure  4.19  PAS staining of goblet cells in mouse airways .............................. 95 
 
Figure  4.20  Statistical analysis of goblet cells in VLP-H/G  
immunized mice ................................................................................................ 97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Tables 
  
xv 
Chapter II 
 
Table 2.1  Kinetics of RSV infection in various inbred  
mouse strains..................................................................................................... 31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Abbreviations 
  
xvi 
RSV: respiratory syncytial virus  
FI-RSV: formalin-inactivated respiratory syncytial virus 
UV-RSV: ultraviolet irradiated respiratory syncytial virus 
MMTV: mouse mammalliary tumor virus 
HCMV: human cytomegalovirus 
HCV: hepatitis C virus 
I.N.: intranasal 
I.P.: intraperitoneal 
I.M.: intramuscular 
Th1: T cell helper 1 
Th2: T cell helper 2 
IFN: interferon 
IL-6: interleukin 6 
IFNb: interferon beta 
TNF-!: tumor necrosis factor-alpha 
MCP-1: monocyte chemoattractant protein-1 
IRF: interferon regulatory factor 
NF-"B: nuclear factor kappa B 
RANTES: regulation upon activation, normal T cell expressed, and secreted 
IFN-#: interferon gamma 
MIP-1!: macrophage inflammatory protein-1alpha 
DC: dendritic cell 
MHC: major histocompabibility complex 
PBMC: peripheral blood mononuclear cells 
NK cell: natural killer cell 
RSV F: RSV fusion protein 
RSV G: RSV attachment protein 
RSV SH:  RSV small hydrophobic protein 
PRRs:  pattern recognition receptors  
PAMPs: pathogen associated molecular patterns  
TLR: toll-like receptor 
MyD88: myeloid differentiation factor 88 
TRIF: TIR-domain-containing adapter-inducing interferon-? 
TIR: Toll-IL-1 receptor 
VLP: virus-like particle 
VLP-H/G: virus-like particle expressing RSV attachment (G) protein 
GCH: goblet cell hyperplasia  
CTL: cytotoxic T lympocyte 
H and E:  hematoxylin and eosin 
PAS: periodic acid Schiff 
  
1 
Chapter I 
Introduction 
 
 Pathogen-induced acute respiratory tract disease is the leading cause of mortality 
among all infectious diseases worldwide.  Of these pathogens, human respiratory 
syncytial virus (hRSV or RSV) is recognized as the most important cause of pediatric 
respiratory tract disease.  In fact, in many areas, it surpasses microbial pathogens as the 
leading cause of pneumonia and bronchiolitis in infants younger than one year old.  
Although RSV is primarily considered a pediatric pathogen, RSV can infect individuals 
of all ages, often multiple times throughout life.  Elderly and immunocompromised 
populations are particularly sensitive to RSV infections, further emphasizing the urgent 
need to develop vaccines against RSV.  RSV is a high priority for vaccine development, 
but to date attempts to develop a vaccine have been unsuccessful.  It is likely that 
understanding the pathogenesis of RSV disease, including the innate immune response to 
infection, will help in designing a safe and effective vaccine.  
 
RSV the virus 
 
 RSV, a member of the paramyxoviridae family of viruses, consists of a single 
stranded, negative sense strand of RNA surrounded by a nucleocapsid. RSV RNA 
encodes for 10 surface and structural proteins important for infection and proliferation of 
the virus (Figure 1.1a).  Five of these proteins are involved in capsid formation and  
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Figure 1.1  RSV structure and genome 
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Figure 1.1  RSV structure and genome 
 
The cartoon in figure 1.1a illustrates the individual components that comprise the  
structure of RSV.  The ribonuclear protein complex (RNP complex) contains genetic 
information important for proliferation of viral progeny.  The RNP complex is 
surrounded by a protein matrix and a lipid envelope that provide protection and structure 
to the virus.  Importantly, glycoproteins including the F and G proteins are shown 
extending out from the lipid capsule.  These proteins are thought to facilitate infection of 
host cells and are important immunogens.  Figure 1.1b depicts the non-segmented linear 
strand of RNA that encodes for 11 RSV proteins.  The relative length in kilobases (kb) of 
each segment is denoted by the ruler.  This single RNA strand is translated from left to 
right.  Protein messages are grouped by color, based on synergy.   
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virus structure or RNA synthesis: the N protein which associates with genomic RNA, L 
protein, the major polymerase subunit, P phosphoprotein, an essential cofactor in RNA 
synthesis, M2-1 and M2-2 proteins, which are involved in transcription and coordinating 
the tempo of transcription and RNA replication, respectively (reviewed in (28)).   
 Following successful assembly of the nucleocapsid, the virus is packaged into a 
lipid bi-layer derived from the host cell membrane during budding.  Four RSV proteins 
associate with the lipid bi-layer to form the viral envelope: M, F, G, and SH (Figure 
1.1b). The matrix (M) protein lines the inner envelope surface and is important in viral 
assembly and budding.  The fusion (F), attachment (G), and small hydrophobic (SH) 
proteins are heavily glycosylated transmembrane proteins (reviewed in (28)). The F and 
G proteins are considered important for infection of host cells and importantly, are the 
only known antigenic determinants for RSV.  The significance of these antigenic 
determinants will be discussed in more detail in later sections.  The F protein is thought 
to mediate direct viral fusion of the viral envelope to the host plasma cell membrane (30).  
F protein remaining on the host plasma membrane facilitates host cell-cell fusion that can 
form syncytia, or large clumps of cells, in vitro.  F is a type I transmembrane protein 
having an N-terminal cleaved signal peptide and a membrane anchor near the C-terminus 
(reviewed in (28)).  Initially, F is synthesized as an inactive F0 precursor that assembles 
into a homotrimer and is activated following cleavage in the trans-Golgi complex by 
cellular endoproteases.  This reaction yields two disulfide-linked F1 subunits and a small 
p27 fragment.  The F1 subunit contains heptad repeats that associate during viral fusion to 
bring viral and host membranes into close proximity (55).  The role of the F0 fragments in 
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directing viral fusion remains largely unexplored, although it has been suggested that the 
F0 of bovine RSV (bRSV, a close relative of hRSV) may play a role in mediating mucous 
secretion in the lungs (179).   
 Initially, the G protein was suggested to be the major attachment protein because 
antibodies against G inhibited attachment of virions to host cells while antibodies against 
F abrogated fusion but not attachment (96). However, unlike other paramyxoviruses that 
require both the G and F proteins for successful attachment, RSV F seems to act 
independently from G to facilitate infection under certain conditions.  For example, 
recombinant RSV lacking the G and SH proteins was able to infect cultured cells and 
induce syncytia formation with wild-type-like efficiency in certain cultured cell lines 
(163).  Additionally, VSV recombinantly engineered to express RSV F protein was able 
to infect and form syncytia in cultured cells (81).  However, RSV lacking G and SH 
proteins was significantly attenuated in vivo, perhaps suggesting a major, but not entirely 
exclusive, role for G in viral attachment (163).   
 The G protein is unlike other paramyxovirus glycoproteins.  It is a type II 
transmembrane protein with a single hydrophobic region near the N-terminal end that 
serves as both the uncleaved signal peptide and a membrane anchor, and it is also 
expressed as a secreted form.  The secreted form lacks the entire 65 amino acid (aa) N-
terminus, including the signal/anchor (72, 97, 138).  Its ectodomain (aa 65-312) is heavily 
glycosylated by N-linked and, primarily, O-linked carbohydrates. The estimated 24-25 O-
linked carbohydrate side chains and 4 N linked side chains increase the molecular weight 
of the protein, synthesized in Vero cells, from 32,500 kD to approximately 90,000 kD 
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(31, 173).  Interestingly, recent studies have suggested an immunomodulatory role for 
both the membrane-bound and secreted forms of the RSV G protein, which will be 
discussed in later sections.  Considerably less is known about the role of the SH protein, 
although some reports suggest that SH may play a minor role in immune surveillance 
(51).  
 The remaining two proteins, NS1 and NS2, are not packaged into the virion.  In 
fact, they appear to be nonessential accessory proteins involved in modulating the host 
response to infection.  Both NS1 and NS2 appear to be involved in dampening IFN 
!/$ production by interfering with IRF-3 and STAT 2 signaling pathways (98, 150, 151).  
Additional evidence suggests that these proteins can antagonize SOCS proteins and likely 
play direct roles in limiting dendritic cell maturation, the latter resulting in weak or 
incomplete activation of protective immune responses (115, 117).    
 
RSV the pathogen 
 
 RSV is the most important cause of respiratory tract disease in infants and young 
children.  This association has been recognized for over 40 years.  The WHO estimates 
that annual infection and mortality figures for RSV infection are 64 million and 160,000, 
respectively, in the United States alone (144, 164).  Roughly 65% of all infants have been 
infected with RSV before 1 year and by 2 years nearly all children have been infected 
with the virus (28).  RSV may also cause repeated infections throughout life.  Both 
primary and repeat infections are associated with a range of illness from common cold-
  
7 
like symptoms to serious lower respiratory tract disease such as bronchiolitis, pneumonia, 
ottis media, and persistent wheezing (73).  Additionally, immunocompromised patients, 
particularly those with T and B cell deficiencies, are highly susceptible to RSV infection 
and exhibit increased risk of developing severe RSV-induced disease.  Notably, RSV can 
cause significant disease in elderly patients and is associated with higher mortality than 
influenza in non-pandemic years (122).  Therefore, RSV is a serious pathogen in infant, 
elderly, and immunocompromised populations.   
 RSV inoculation can occur through mucous membranes of the eyes and nose by 
either aerosol or direct contact modalities.  Epithelial cells of both the upper and lower 
respiratory tract are major targets of RSV infection and serve as temporary reservoirs for 
the virus during active infection.  In particular, ciliated cells of the small bronchioles and 
type 1 pneumocytes are targeted for infection.  However, non-ciliated epithelial cells, 
intraepithelial dendritic cells, and resident macrophages can, also, likely be infected by 
the virus (62).  RSV is a cytopathic virus that causes necrosis of epithelial cells and 
proliferation of bronchiolar epithelial cells.  Furthermore, some specialized respiratory 
cell functions like cilial motility are diminished (1, 120).  A peribronchiolar mononuclear 
infiltrate consisting primarily of monocytes, T cells, and neutrophils is observed during 
the initial stages of infection, along with submucosal edema and mucous secretion.  
Interestingly, a pronounced eosinophilic infiltrate is observed in some severe RSV 
disease patients, although the mechanisms for this infiltration are not yet clearly defined 
(reviewed in (28)).  Therefore, the severity and duration of disease, in part, likely depends 
  
8 
on the amount of airway obstruction occurring from virus/host interactions, including 
sloughing of dead epithelial cells, mucus secretion, and accumulating immune cells.   
 
RSV pathogenesis 
 
 The observation that RSV can induce such a diverse range of symptoms suggests 
that both environmental and genetic factors likely play key roles in disease pathogenesis, 
although these processes remain poorly defined at best. Certain environmental factors, 
such as infant age (<6 months), premature birth (<35 weeks of gestation), low birth 
weight, immunosuppression, congenital heart disease, frequency of RSV infections, and 
old age have been associated with RSV disease.  Increased risk of exposure, such as day 
cares, hospitalizations, and multiple siblings also may also contribute to disease 
susceptibility (170).  However, it is important to remember that only a small percentage 
(2-5%) of all children infected with RSV develop severe disease, while the majority of 
patients develop mild respiratory symptoms that often remain undiagnosed, thereby 
complicating the search for disease susceptibility markers.   Also, the immunosupressed 
and elderly patients, two populations exhibiting varied defects in important immune 
regulatory mechanisms that control infection, are at increased risk of developing RSV 
disease, indicating that environmental factors alone cannot fully account for disease 
susceptibility. 
 Although infant health and underlying disease can contribute to RSV 
susceptibility, more than 60% of all infants hospitalized were previously healthy, 
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suggesting that a possible genetic predisposition to disease may influence susceptibility 
(122).  This hypothesis is substantiated, in part, because 50% or more of infants 
hospitalized with RSV infection in the first 6 months of life can exhibit recurrent 
wheezing up to 11 years or more of age.  Also, severe RSV disease during infancy may 
predispose for asthma or asthma-like symptoms later in life (37% of RSV bronchiolitics 
vs. 5.4% of controls) (147).  Recently, evidence suggesting genetic polymorphisms in 
important innate immune signaling pathways ranging from viral recognition to 
inflammatory processes targeted towards elimination of the virus may predispose for 
severe RSV-induced disease (9, 16, 90, 125, 140, 165).  These observations suggest that 
host responses to RSV, particularly innate immune responses, may be an important 
component of disease pathogenesis.  Therefore, much of the current RSV research is 
focused on understanding how host immune responses may contribute to RSV disease to 
better facilitate development of therapies and vaccines.   
 
Role of innate immunity in recognizing RSV 
 
 If a virus successfully transverses host membranes and reaches its target cells, a 
myriad of host innate immune processes are poised to sense the virus and alert the 
immune system to the presence of the invading pathogen.  These innate immune 
mechanisms exist to sense pathogens, contain the spread of the pathogen from one host 
cell to another, and to provide the correct immunologic signals needed to ultimately 
eliminate the pathogen from the infected area.  Leukocytes and resident tissues express a  
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Figure 1.2  TLRs are PRRs that recognize invading pathogens by their PAMP 
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Figure 1.2  TLRs are PRRs that recognize invading pathogens by their PAMP 
 
 
TLRs are pattern recognition molecules (PRRs) expressed on host cell surfaces and in 
host cell endosomes that recognize conserved molecular structures (PAMPs) on bacteria, 
fungi, or viruses.  TLR2 and TLR4 can recognize both bacterial and viral motifs while 
TLR3,7,8,9 can recognize viral motifs. Once TLRs recognize their cognate ligand, they 
activate distinct signaling pathways (i.e., MyD88 and TRIF) that ultimately initiate 
transcription of host defense genes.   
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variety of pattern recognition receptors (PRRs) that sense pathogen-associated molecular 
patterns (PAMPs), evolutionarily conserved molecules among families of different 
microbes.  Included in this family of PRRs are Toll-like receptors (TLRs).  TLRs interact 
with PAMPs, including RSV, thereby initiating a complex cascade of signals that 
promote host defense genes (Figure 1.2). TLR signaling occurs through a common Toll-
interleukin-1 (IL-1) receptor (TIR) domain.  All TLRs recruit MyD88 to the TIR with the 
exception of TLR3, which recruits TIR domain containing adaptor inducing beta 
interferon (TRIF).  MyD88 signaling activates transcriptional gene regulators including 
mitogen-activated protein kinase, NF-"B, and IFN regulatory factors (IRF).  These 
transcriptional regulators promote cytokine, chemokine, and interferon (IFN) production 
that make up the inflammatory mileu at the sites of infection (reviewed in (3, 10, 
158))(Figure 1.3).   
 As indicated, TLRs can recognize a diverse range of microbial signatures.  TLRs 
are divided into two major categories: TLRs expressed on cell surfaces or in endosomes.  
Thirteen different TLRs have been identified in humans and eleven in mice.  TLRs 
recognize various components of bacteria, fungi, protozoa, and, in particular, viruses.  
Certain TLRs implicated in recognizing viral components include TLR3 (dsRNA), TLR 
7/8 (ssRNA), TLR9 (dsDNA)(83, 148), which are located in endosomes, and TLR2 
(HCMV, HCV core)(27, 32), TLR4 (MMTV, RSV F protein)(90, 137), and TLRs 1 and 
6, located on cell surfaces.  TLRs 1 and 6 are unique amongst all TLR because they 
dimerize with TLR2 to propagate signaling(3).  Endosomal TLR ligation drives IRF-3/7  
activity leading to the production of IFN-!/$, a critical pleiotropic activator of anti-viral  
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Figure 1.3  TLR/pathogen interactions induce innate signaling responses within host cells  
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Figure 1.3  TLR/pathogen interactions induce innate signaling responses within host cells 
 
Intracellular TLR stimulation pathways are depicted in this cartoon.  Engagement of all 
TLRs by foreign antigens except TLR3 leads to MyD88 activation.  Once activated, 
MyD88 initiates a signaling cascade of phosphorylation events that promote IRAK-4 and 
TRAF6 activation.  TRAF6 can activate AP-1 and NF-"B.  AP-1 and NF-"B are 
transcription factors that, once activated, translocate to the nucleus and initiate 
transcription of inflammatory mediators including IL-1$, IL-6, IL-8, IL-12, TNF-!, 
CCL2, CCL3, and CCL5.  Additionally, MyD88 activation following TLR7,8,9 ligation 
initiates a signaling cascade that activates the transcription factor IRF-7.  TLR3 ligation 
leads to TRIF activation.  This event leads to TBK1 activation and to the activation the 
transcription factor IRF-3.  Furthermore, both TLR2 and TLR4 share a common 
intracellular signaling molecule, Mal, that interacts with MyD88 to propagate 
downstream signaling events. TLR4 is unique among all TLRs because it can activate 
both the MyD88 dependent and TRIF dependent signaling cascades.  If the TRIF and 
MyD88 pathways are both engaged either through TLR4 signaling or the combinatory 
effects of different TLR signaling pathways (i.e. TLR2 and TLR9) the resulting 
activation of NF-"B, AP-1, and IRF-3/7 promote the transcription of Type I IFN.  Thus, 
TLR activation initiates a series of highly complex and intricate pathways targeted 
against the invading pathogen.   
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responses (148). 
 Surface TLR ligation is important for NF-"B driven responses, including pro-
inflammatory cytokines such as IL-1$, IL-6, IL-8, IL-12, TNF-! and chemokines such as 
CCL2 (MCP-1), CCL3 (MIP-1!), CCL5 (RANTES), important molecules involved in 
inflammation and chemotaxis of leukocytes to sites of infection (reviewed in (84)).  
Unlike other TLRs, TLR4 ligation can propagate signaling through both NF-"B and IRF 
pathways because it contains an intracellular MyD88 and TRIF recruitment site 
(reviewed in (84)). TLRs 3, 7, and 4 plus CD14 are known to interact with RSV, thereby 
providing multiple pathways by which the host innate immune response can mediate 
responses to RSV infection (90, 141, 142).  
 
Linking innate and adaptive immune responses against RSV 
 
 Lung epithelial cells and resident antigen presenting cells (APCs), including 
macrophages and dendritic cells (DCs), the first line of innate immune sentinels, express 
TLRs that recognize RSV motifs and coordinate the initial inflammatory response against 
RSV.  The inflammatory mileu generated during these interactions has direct effects on 
virus replication and recruitment of additional leukocytes, including NK cells, 
neutrophils, monocytes, T cells, and circulating DCs into the lungs, each playing critical 
roles in the establishment of protective immune responses (140, 149, 177).  DCs are 
unique APCs that can link the innate and adaptive immune responses against pathogens, 
including RSV, by undergoing functional maturation (Figure 1.4).  This process is 
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defined by heightened cytokine production, including IL-12, IL-1$ and TNF-!, that can 
further augment inflammation, increase expression of MHC I and II molecules, and 
increase expression of co-stimulatory molecules CD86, CD80, and CD40(88).  In this 
maturation state, DCs promote adaptive immunity through the activation and subsequent 
clonal expansion of both T and B lymphocytes.  Furthermore, the make-up of the 
inflammatory mileu directly impacts a DCs ability to polarize the type (i.e., Th1-like or 
Th2-like) of acquired immune response generated following pathogen recognition.  
Interestingly, research has shown that a weak or incomplete Th1 polarizing inflammatory 
mileu can lead to Th2-like responses (140).  While most individuals who do not develop 
RSV-induced disease seem to establish protective Th1-like responses, RSV-susceptible 
individuals seem to exhibit Th2 immune responses, similar to asthmatic responses, that 
are thought to be involved in disease pathogenesis (reviewed in (12)).  Therefore, disease 
susceptibility may be multi-factorial, encompassing underlying genes that control 
immune responses to RSV and/or the ability of RSV to influence major components of 
the innate immune response including the initial inflammatory mileu. 
 
Host adaptive immune responses to RSV 
 
 RSV infection, like other respiratory viral infections, is usually completely 
resolved by innate and adaptive immunity.  Host immune responses, both soluble and 
cell-mediated, have been proposed to be important for protection against RSV infections 
(5, 25, 26, 29, 58, 99, 145). The RSV F protein, one of the two major antigens expressed  
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Figure 1.4  Dendritic cells (DCs) link innate and adaptive immune responses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Dendritic cells (DCs) link innate and adaptive immune responses 
 
Immature Dendritic cells (DCs) survey host tissues for the presence of foreign pathogens 
including viruses.  Using receptors such as TLRs immature dendritic cells can sense 
invading virus and alert the immune system to their presence.  Both the activation 
stimulus, including direct TLR/pathogen interactions, and environmental factors within 
the infected host tissue can greatly influence the type (Th1 or Th2) of acquired response 
that a DC can generate.  It is thought that strong inflammatory signals (illustrated by a 
heavy arrow) lead to a mature Th1 polarizing DC while weak or blunted signals 
(illustrated by skinny arrow) lead to a mature Th2 polarizing DC (140).   
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on virion surfaces (29), is thought to be an important target of neutralizing and protective  
antibodies (29, 49, 159).  Indeed, monoclonal antibodies specific for the RSV F protein 
are used clinically for RSV disease prophylaxis in high-risk infants.  However, the 
protective effects quickly wane due to the half-life of circulating antibodies (between 21-
28 days) (6, 128).  The F protein is also a major target of CD8 T cells in mice (24), but 
the association between cell-mediated immunity and protection from RSV disease in 
humans has not been well established (132).  The role of the G protein, the other major 
antigen on virion surfaces, in stimulating protective immune responses is less clear, 
although it is thought that antibodies to this molecule do have a role in protection (70, 
111, 113).  CD8 T cell epitopes have not been defined for the G protein however recent 
studies have implicated the G protein in defining CD8 T cell responses (18).     
 The coordinated efforts of innate and adaptive immunity are sufficient to clear 
most primary infections.  However, the establishment of long-term protection is essential 
to avoid subsequent infections and likely to prevent RSV induced disease.  The fact that 
the overwhelming majority of individuals infected with RSV can and will be re-infected 
with the virus, often times during the same infection cycle, suggests that long-term 
protective immune responses are not effectively established.  Furthermore, the 
observation that certain populations exhibit aberrant responses to RSV infection, 
including severe RSV-induced disease, suggests that not only ineffective, but also, 
deleterious, and perhaps misguided (i.e., Th2 responses greater than Th1) immune 
responses are likely being induced.  Possible factors contributing to these observations 
include age at time of infection, underlying genetic factors that limit innate immune 
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activation, poor immunogenicity of RSV antigens, and/or viral mechanisms that subvert 
immune surveillance and/or limit robust immune activation.  
 
Host factors that contribute to disease susceptibility 
 
 Perhaps the most compelling evidence that host immune responses can cause 
severe RSV disease is derived from early RSV vaccine trials in infants using a formalin-
inactivated RSV (FI-RSV) preparation (82).  The vaccine was poorly protective and, in 
RSV naïve individuals, it primed for more severe RSV disease upon subsequent natural 
RSV infection.  Surprisingly, approximately 80% of vaccinated individuals were 
hospitalized with enhanced RSV disease, and two patients died.  Retrospective analysis in 
both humans and animal models revealed that poor neutralizing antibodies were 
generated against RSV, suggesting that incomplete antibody affinity maturation might 
contribute to enhanced disease (41), along with other factors as well.  For example, 
further analyses revealed a strong Th2-like biased immune response characterized by 
Th2-like cytokines (IL-4, IL-5, and IL-13), eosinophilia, goblet cell 
hyperplasia/metaplasia, mucous overproduction, IgE greater than IgG antibody 
production, and airway hypersensitivity against subsequent RSV infections after FI-RSV 
vaccination (12, 14, 169).  Therefore, the host immune system can greatly influence 
disease pathogenesis.  While these data are highly suggestive of aberrant immune 
activation leading to RSV disease, the relevance of vaccine-enhanced disease to natural 
RSV disease is still somewhat unknown.  
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 Although post-hoc analysis of human samples administered FI-RSV and animal 
models have provided some answers to vaccine-enhanced disease, the underlying host 
mechanisms that contribute to natural disease still remain poorly defined.  Growing 
evidence suggests that defects in innate immunity, particularly in TLR signaling, may 
contribute to RSV disease susceptibility.  Our lab previously reported that RSV F protein 
interacts with TLR4, which can signal through MyD88, to activate an innate immune 
response (71, 90).  These results have been confirmed and extended by others, further 
supporting the hypothesis that TLR signaling is involved in the innate immune response 
to RSV (16, 61).  Recently Awomoyi et al. suggested that defects in TLR signaling, 
TLR4 in particular, may be linked to RSV-induced pathology in pre-term high risk 
infants (9), although the overall effect of TLR4 on RSV pathogenesis remains somewhat 
unclear.  Supporting these findings, Holt et al. demonstrated that PBMCs isolated from 
children with TLR4 mutations exhibited decreased NF-"B activation and subsequently 
displayed decreased cytokine production in response to RSV, suggesting that weakened 
immune responses may contribute to RSV-induced disease (165).  Together, these studies 
provide evidence suggesting that TLR-dependent signaling is important for activating 
early inflammatory responses to RSV and that aberrant TLR signaling may promote 
RSV-induced disease.   
 Adaptive immune responses, in addition to innate responses, may play key roles 
in determining susceptibility to RSV-induced disease.  Studies in mice revealed that CD4 
and CD8 T cells can mediate disease severity, and observations from humans with severe 
combined immunodeficiency further suggest a T cell component to RSV-enhanced 
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disease (25, 26, 57, 123, 171).  Additionally, a genetic polymorphism in the gene that 
encodes the Th2 cytokine, IL-4, that increased expression, was found to be associated 
with increased susceptibility to RSV (13, 136, 139). Collectively, these and other studies 
support the hypothesis that immune-mediated events likely greatly contribute to RSV 
disease and underscore the need to examine further how RSV/host interactions initiate 
immune responses that may skew towards or away from RSV disease.   
 
Virus factors that contribute to disease susceptibility 
 
 RSV has an extremely high rate of infectivity and is often considered one of the 
most contagious human pathogens.  Surprisingly, RSV can cause repeated infections 
throughout life, despite having limited strain and antigenic diversity.  In fact, RSV has a 
single serotype with two major antigenic groups (A and B).  Between the two serotypes 
the F protein is highly conserved (90% sequence homology and 50% antigenic identity), 
while the G protein is more divergent (53% sequence homology and 1-7% antigenic 
identity) (reviewed in (28)).  Unlike other respiratory viruses, such as influenza, that can 
evade immune recognition by antigenic drift and/or antigenic shift, RSV causes disease 
with little to no modification, suggesting that RSV possesses compensatory mechanisms 
that can limit or subvert immune surveillance and/or activation.  RSV is thought to cause 
pathology, both directly and indirectly, through limited cytopathic effects on epithelial 
cells (176) and modulation of host immune responses, respectively.  This hypothesis has 
been substantiated by studies indicating that the NS1/NS2 and RSV G proteins help the 
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virus evade innate immune activation.  First, the NS1/NS2 proteins can effectively block 
synthesis of host Type I IFN (102).  Mechanistically, NS1/NS2 can block IRF-3 
activation and can down-regulate JAK/STAT pathways, specifically STAT2, both of 
which are critical for Type I IFN production (102).  Furthermore, RSV infection of 
STAT1 knockout mice revealed a role for JAK/STAT responses in modulating Th1/Th2 
balance, i.e., STAT1 knock-out mice exhibited heightened Th2 responses following RSV 
infection, suggesting that manipulation of these host proteins may increase susceptibility 
to RSV disease in an otherwise normal host (44).   
 The RSV G protein contains a number of important features that are thought to 
both limit immune activation and contribute to disease susceptibility.  Initial reports 
suggested immunizations containing the G protein alone (i.e. subunit vaccine) or vaccinia 
virus-delivered G protein elicited an unbalanced, Th2-dominated immune response (59, 
68, 124).  However, more recent studies suggest that the unbalanced response observed in 
these cases may be due to the soluble form of the G protein (sG), not the membrane 
bound form (mG) or to the method of antigen delivery (78, 79). It has been suggested that 
sG protein, which represents 80% of G protein released from cells within 24 hours post- 
infection (42, 79), can subvert host immune detection in part by inhibiting Toll-like 
receptor 3- and 4- mediated IFN-$ production and that the Th balance can be restored 
using TLR adjuvants (66, 146). Furthermore, infection of human epithelial cells and 
monocytes with RSV lacking G resulted in increased NF-"B derived cytokine (IL-6, IL-
8) and chemokine (RANTES) production, suggesting that RSV proteins can dampen 
advantageous host pro-inflammatory responses (134).  However, other studies have 
  
23 
suggested that disease enhancement is related to two mucin-like domains (GCRR) in the 
G protein ectodomain (GCRR) (56, 92). This GCRR domain includes a CX3C chemokine 
motif that has been hypothesized to affect leukocyte trafficking to lungs (69), indirectly 
promoting Th2 responses by inhibiting important immune pathways that support Th1 
responses.  Additionally, the GCRR has been hypothesized to limit neutralizing antibody 
function by acting as an antigen decoy, thereby limiting effective host responses against 
RSV (19). Therefore, it seems highly possible that proteins synthesized by RSV during 
active replication may directly contribute to RSV induced disease by manipulating the 
natural host response to RSV infection.   
 Research aimed at understanding the mechanisms by which RSV interacts with 
host immune systems and vice versa has begun to establish a somewhat less murky 
picture of how these interactions can skew subsequent immune responses either towards 
or away from disease.   Insights from the early FI-RSV vaccine trials, coupled with new 
information related to host genetic susceptibilities to RSV and an increased 
understanding of how RSV limits host innate immune responses, is guiding research 
efforts to develop vaccines against RSV, but these insights also underscore an important 
cautionary point.  Since immune responses are, in part, responsible for exacerbated 
disease pathology, great care must be taken in designing vaccines that can be both 
protective and safe in humans.   
 
Animal models used to study RSV 
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 Resulting from the failed RSV vaccine trials of the 1960s, suitable animal models 
have been sought to elucidate possible mechanisms of enhanced disease as well as basic 
pathways involved in host responses to RSV infection.   Given the potential for 
heightened morbidity and mortality from an RSV vaccine, animals including mice, cotton 
rats, calves, and primates can be used as useful surrogates to study RSV pathogenesis 
(23, 28, 40, 59, 119, 130, 160, 169).  While none of the models can definitely predict 
human responses to RSV, each model has been useful in determining certain aspects of 
disease susceptibility and pathogenesis.  Mice provide a particularly useful model to 
study RSV for a number of reasons, including availability of immunologic reagents, 
relative ease of care, wide variety of inbred and congenic strains, and similarity between 
mouse and human genomes (approximately 99% of 30,000 genes are similar).  
Furthermore, different inbred mouse strains can display variable degrees of susceptibility 
to RSV, thereby providing a highly useful tool to study underlying genes that confer 
susceptibility or resistance to disease.  For example, inbred C57BL6/J mice are naturally 
more resistant to RSV infection than BALB/c mice which display a heightened 
susceptibility to infection (152).  In addition to natural susceptibility differences, certain 
mice, BALB/c in particular, faithfully reproduce many aspects of FI-RSV vaccine 
enhanced disease, thereby providing researchers with a useful model to study safety and 
efficacy of experimental vaccines (131, 169).  Interestingly, cotton rats (Sigmodon 
hispidus) reproduce aspects of FI-RSV vaccine-enhanced disease and are approximately 
100 times more permissive to RSV infection than mice, but the small number of 
immunologic reagents limits the usefulness of this model.  Furthermore, because mice 
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and humans can differ in responses to certain vaccines, primates can be used to more 
accurately predict immunologic responses, but research with primates is generally cost-
prohibitive.  Therefore, the majority of research examining RSV pathogenesis and 
vaccine responses is often confined to studies in suitable mouse models.   
 
Developing a novel vaccine strategy for RSV 
 
Previous attempts to develop RSV vaccine 
  
 As previously indicated, FI-RSV vaccination not only resulted in poor protection 
but also, disease enhancement and, in some cases, death upon subsequent RSV infection 
(82, 85).  Many subsequent studies have attempted to define the reasons for this response.  
These studies consistently showed that enhanced disease is accompanied by unbalanced 
Th2-biased cytokine responses, weak CD8+ T cell responses, pronounced eosinophilia, 
and induction of low affinity and non-neutralizing antibodies (39, 41, 133, 135, 169). 
Less clear are the precise properties of the FI-RSV vaccine that led to these results 
(reviewed in (99)).  Absence of these characteristics of enhanced disease is now one of 
the benchmarks for development of a successful RSV vaccine.  Subunit vaccines 
designed to exploit the potential immuogenic potential of the G and F proteins alone have 
had limited success in mice (65, 67, 68).  One interesting strategy, incorporation of G 
and/or F protein along with a known TLR agonist, has yielded protective effects in mice 
(66), but these adjuvants have not been approved for use in humans in the United States.  
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Thus far, no vaccine approach reported in animal models has translated into a licensed 
vaccine for use in humans. 
 
Virus-like particles as vaccine candidates 
 
 A virus-like particle (VLP) vaccine strategy has not been reported for RSV. VLPs 
are large particles, the size of viruses, composed of repeating structural arrays on their 
surfaces and in their cores, structures that mimic those of infectious viruses ((reviewed in 
(77, 121)).  VLPs are formed by the assembly of the structural proteins and lipids into 
particles but without the incorporation of the viral genome.  Thus, VLPs are incapable of 
multiple rounds of infection typical of an infectious virus, yet they retain the superb 
antigenicity of virus particles.  Native viral antigens arrayed on VLP surfaces and in their 
cores likely contribute to potent humoral responses, CD4 T cell proliferation, and 
expansion of cytotoxic CD8 T cells, unlike less immunogenic subunit vaccines often 
comprised of individual purified viral proteins (20-22, 53, 94, 101, 143, 156). The 
potential of VLPs as safe, effective vaccines for viral disease is increasingly recognized.  
Indeed, two VLP vaccines are now licensed for use in humans, the papilloma virus 
vaccine and the hepatitis B virus vaccine, and a number of other VLP vaccines are being 
evaluated in preclinical and clinical trials (reviewed in (77)). Therefore, VLPs expressing 
one or both RSV glycoproteins may be an attractive strategy for designing an effective 
RSV vaccine.   
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VLPs as candidate vaccine for RSV 
 
 There is only one report of VLPs formed with RSV proteins (162). These particles 
have not been well characterized and the efficiency of VLPs released from infected cells 
is unknown.  Furthermore, their detection required incorporation of a minigenome.  
However, it has previously been reported that the expression of the four major structural 
proteins of NDV, an avian paramyxovirus, results in the very efficient release of particles 
that structurally and functionally resemble virus particles ((127) McGinnes et al., in 
preparation).  Further, these particles (ND VLPs) stimulated potent anti-NDV immune 
responses in mice, including neutralizing antibody responses (McGinnes et al., in 
preparation).  These results suggest that ND VLPs could serve as a platform for the 
expression of antigens from human viruses, including RSV G and F proteins, and that 
these particles could serve as an effective RSV vaccine.  
 
Research objectives 
  
 In chapters II and III the role of TLRs in activating innate immune responses 
against RSV has been explored.  We examined whether RSV could promote activation of 
innate immunity through TLR2 signaling.  TLR2 is expressed on the surface of immune 
cells and tissues as a heterodimer complex with either TLR1 or TLR6 (3).  TLR2 and 
TLR1 or TLR2 and TLR6 complexes recognize bacterial peptidoglycan motifs as well as 
a diverse range of viruses, including HCV, HSV, LCMV, and HCMV and strongly 
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promote early innate inflammatory responses after viral recognition (27, 32, 89, 177).  
Genetic analysis and vaccine studies in BALB/c mice indirectly suggest that TLR2 
signaling may be involved in RSV recognition.  However, these studies did not 
investigate whether TLR2 directly interacts with RSV (36, 66, 76).  We wished to 
examine further the inferred relationship between RSV and TLR2 because identifying 
novel pathways by which RSV activates innate immunity could aid the development of 
safe and effective RSV vaccines.  In this study, we demonstrate that RSV interacts with 
TLR2 and TLR6, but not TLR1, and this interaction activates innate immunity. 
 Furthermore, in chapter IV, we report that the ectodomain of the RSV G protein, 
fused to the cytoplasmic tail (CT) and the transmembrane (TM) domain of the NDV 
hemagglutinin-neuraminidase (HN) protein, can be efficiently incorporated into VLPs 
containing the NDV NP and M protein, and these particles can be quantitatively prepared 
and used as an immunogen. We demonstrated that immunization with these particles 
stimulated robust soluble and cell-mediated immune responses.  Additionally, they 
conferred protection in BALB/c mice, following live RSV challenge, characterized by 
increased viral clearance in lung tissue.  Finally, infectious RSV challenge of mice 
following VLP-H/G immunization did not result in enhanced lung pathology typified by 
FI-RSV immunization (33, 34, 119) 
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Chapter II 
Introduction 
 
 The role of TLR in activating innate immune responses against RSV has become 
increasingly clear.  Previous studies in mouse models lacking particular TLRs clearly 
demonstrated an association between RSV and host TLRs in activating intracellular 
signaling pathways that lead to the induction of pro-inflammatory innate immune 
responses.  These studies have implicated particular TLRs, including TLR3, 4, and 7 in 
mediating innate immune responses to RSV.   In this chapter we describe an additional 
TLR pathway, TLR 2/6, that is important for activating innate immunity against RSV.  
The involvement of multiple TLRs in the host innate immune response is likely very 
important because signals generated by different TLRs after pathogen recognition likely 
activate different components of the innate immune response, ultimately shaping host 
acquired immune responses which lead to proper viral clearance, or in certain instances, 
may lead to a RSV induced disease phenotype.  
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Results 
 
BALB/c mice exhibit differences in sensitivity to TLR2 ligands and RSV compared 
to C57BL6/J mice 
 Kinetic studies were conducted to examine the duration of RSV infection in 
different inbred strains of mice.  Data shown here confirm previous reports suggesting 
that C57BL6/J mice are resistant to RSV infection, as based on peak virus titer and 
detection of virus in lung homogenates of infected mice throughout the duration of the 
time course (Table 2.1) (162).  Furthermore, BALB/c mice are more permissive to RSV 
infection when compared to C57BL6/J mice and to semi-permissive B6.129F2/J mice.  
At the peak of virus infection (day 4), BALB/c mice had 30-fold more virus in lung 
homogenates than C57BL6/J mice.  Therefore, experiments were conducted to further 
characterize the early inflammatory response to RSV in BALB/c and C57BL6/J 
macrophages.  Macrophages from BALB/c mice showed decreased responsiveness to live 
RSV stimulation and the TLR2 agonist Pam2CSK4 (Figure 2.1).  Furthermore, BALB/c 
macrophages showed decreased upregulation of surface TLR2 following RSV 
stimulation, suggesting a possible association between RSV and TLR2 signaling (Figure 
2.2).  Since mice lacking specific TLRs are only available on the C57BL6/J background, 
we wished to test the aforementioned association in this model.   
TLR2 and TLR6 but not TLR1 recognize RSV 
   The role of TLRs in response to RSV was examined using TLR deficient mice.  
Thioglycollate-elicited peritoneal macrophages from C57BL/6, TLR2 KO, and TLR4 KO  
  
31 
Table 2.1  Kinetics of RSV infection in various inbred mouse strain 
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Table 2.1 Kinetics of RSV infection in various inbred mouse strains 
 
Wild-type C57BL/6, BALB/c, and B6.129F2/J mice were infected i.n. with RSV A2  (2.4 
x 10
6 
PFU/mouse).  Lung samples were collected post-infection at the time-point 
indicated and enumerated for PFU using an immunoplaque assay described in the 
methods section.  Mean titer is represented as log10 PFU/gram of lung tissue +/- SEM.  
LLD indicates below lower limit of detection.  ND indicates not determined. 
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Figure 2.1  C57BL6/J PECs are more responsive to TLR ligands and RSV than BALB/c 
PEC 
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Figure 2.1  
 
C57BL6/J PECs are more responsive to TLR ligands and RSV than BALB/c PECs 
 
Macrophages were harvested four days after thioglycollate treatment from C57BL6/J and 
BALB/c mice.  Macrophages were stimulated with RSV (0.3 MOI), UV-inactivated RSV 
(0.3 MOI equivalent), LPS (TLR4 ligand, 100 ng/ml), Pam2CSK4 (TLR2 ligand, 
100ng/ml), or Vero cell lysate (50 ul) in the presence of Brefeldin A as indicated.  Cells 
were stained for CDllb, permeabilized, and stained for intracellular TNF-!.  Values 
indicate % of CDllb
+
 macrophages producing TNF-!.  TNF-! production (black line) 
was compared to isotype control (grey line). 
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Figure 2.2  C57BL6/J PECs express more surface TLR2 than BALB/c PECs after RSV 
stimulation 
 
 
 
 
Figure 2.2  C57BL6/J PECs express more surface TLR2 than BALB/c PECs after RSV 
stimulation 
 
Macrophages were harvested four days after thioglycollate treatment from C57BL6/J and 
BALB/c mice.  Macrophages were stimulated with RSV (0.3 MOI), UV-inactivated RSV 
(0.3 MOI equivalent), Vero cell lysate (50 ul), or medium alone (50 ul) for 24 hours. 
Cells were harvested and stained for CDllb and TLR2 expression.  Values indicate mean 
fluorescence intensity (MFI) of TLR2 expression on CDllb
+
 macrophages.  
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mice were stimulated with RSV in the presence of Brefeldin A, and intracellular cytokine 
levels were measured by flow cytometry.  Macrophages from both TLR2 KO and TLR4 
KO mice produced lower levels of intracellular TNF-! compared to wild-type cells 
following RSV infection (Figure 2.3).  Interestingly, macrophages from TLR2 KO mice 
produced the lowest levels of TNF-!, i.e., less TNF-! compared to TLR4 KO mice and 
wild-type mice (4% vs. 33% and 51% respectively), suggesting a major role for TLR2 in 
the induction of pro-inflammatory cytokines following RSV stimulation.  Controls 
indicated that TLR2 KO mice responded normally to LPS (TLR4 ligand) stimulation and 
that TLR4 KO mice responded normally to Pam2CSK4 (TLR2 ligand).  
 To examine whether RSV replication was required to elicit TNF-! production, 
wild-type macrophages were stimulated with live RSV or UV-inactivated RSV 
(confirmed by immunoplaque assay, data not shown) and intracellular TNF-! was 
measured.  The response to RSV and RSV-UV was equivalent, indicating that RSV 
replication was not required to stimulate intracellular TNF-! production (Figure 2.4).  To 
limit the possibility that contaminating products in the Vero cell-propagated RSV might 
activate TLR2 signaling, sucrose-purified RSV and UV-inactivated purified RSV (a 
generous gift from Dr. Trudy Morrison) were used to stimulate wild type macrophages.  
RSV was purified using methods previously described (54, 87).  Purified RSV stimulated 
wild-type macrophages equivalently to Vero cell-propagated RSV, indicating that RSV 
itself, and not contaminating products in the medium, activated TLR2 signaling (Figure 
2.5).         
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Figure 2.3  TLR2 associates with RSV 
 
 
 
 
Figure 2.3  TLR2 associates with RSV 
 
Macrophages were harvested four days after thioglycollate treatment from wild type, 
TLR2 KO, and TLR4 KO mice.  Macrophages were stimulated with RSV (0.3 MOI), 
LPS (TLR4 ligand, 100 ng/ml), or Pam2CSK4 (TLR2 ligand, 100 ng/ml) for 24 hours in 
the presence of Brefeldin A as indicated.  Cells were stained for CDllb, permeabilized, 
and stained for intracellular TNF-!.  Values indicate % of CDllb+ macrophages 
producing TNF-!.  TNF-! production (black line) was compared to isotype control (grey 
line). 
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Figure 2.4  RSV replication is not required to elicit TLR2 responses 
 
 
 
 
 
 
Figure 2.4  RSV replication is not required to elicit TLR2 responses 
 
Macrophages were harvested four days after thioglycollate treatment from wild-type 
mice.  Macrophages were stimulated with Pam2CSK4 (TLR2 ligand, 100 ng/ml), LPS 
(TLR4 ligand, 100 ng/ml), RSV (0.3 MOI), UV-RSV (0.3 MOI equivalent), Vero cell 
lysate (50 ul),or UV-Vero cell lysate (50 ul), for 24 hours in the presence of Brefeldin A.  
Cells were stained for CDllb, permeabilized, and stained for intracellular TNF-!.  Values 
indicate % of CDllb
+
 macrophages producing TNF-!.  TNF-! production (black line) 
was compared to isotype control (grey line). 
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Figure 2.5  Sucrose-purified RSV stimulates PECs similar to Vero cell-propagated RSV 
 
 
 
 
 
Figure 2.5  Sucrose-purified RSV stimulates PECs similar to Vero cell-propagated RSV 
 
 
Macrophages were harvested from wild-type mice four days after thioglycollate 
treatment. Wild-type macrophages were stimulated with sucrose purified RSV (0.02 
MOI) or UV-inactivated sucrose purified RSV (0.02 MOI equivalent) (d).  Cells were 
stained for CDllb, permeabilized, and stained for intracellular TNF-!.  Values indicate % 
of CDllb
+
 macrophages producing TNF-!.  TNF-! production (black line) was compared 
to isotype control (grey line). 
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Figure 2.6  TLR2 dimer partner TLR6, but not dimer partner TLR1, recognizes RSV 
 
 
 
 
 
 
 
 
Figure 2.6 TLR2 dimer partner TLR6, but not dimer partner TLR1, recognizes RSV 
 
Macrophages were harvested four days after thioglycollate treatment from wild type, 
TLR1 KO, TLR2 KO, and TLR6 KO mice.  Macrophages were stimulated with RSV (0.3 
MOI), LPS (TLR4 ligand, 100 ng/ml), or Vero cell lysate (50 ul) for 24 hours in the 
presence of Brefeldin A.  Cells were stained for CDllb, permeabilized, and stained for 
intracellular TNF-!.  TNF-! production (black line) was compared to isotype control 
(grey line). 
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TLR 2 and TLR 6 but not TLR1 initiate inflammatory responses following ligation 
with RSV 
 Since TLR2 can partner with either TLR1 or TLR6 on the cell surface to 
propagate downstream signaling, we examined whether TLR1 or TLR6 in conjunction 
with TLR2 was involved in RSV signaling.  Wild type, TLR2 KO, TLR1 KO, and TLR6 
KO macrophages were stimulated with RSV, and TNF-! levels were measured.  A role 
for TLR6, but not TLR1, was observed in RSV-induced, TLR-mediated cytokine 
production (Figure 2.6).  As expected, MyD88 KO mice, lacking signaling via TLR2, 
TLR1, and TLR6, did not produce TNF-! in response to RSV (data not shown).   
We further examined the role of TLRs in cytokine and chemokine secretion 
following RSV challenge by measuring cytokine protein levels from in vitro cultured 
macrophages using ELISA.  Macrophages from TLR2 KO and TLR6 KO mice produced 
significantly less IL-6 (Figure 2.7), and CCL2 (MCP-1) (Figure 2.8) compared to wild- 
type cells following RSV infection.   
Additionally, a role for TLR4 in the production of inflammatory cytokines IL-6 
and CCL2 was observed in the TLR4 KO mice.  CCL5 (RANTES) production was also 
decreased in both TLR2 KO and TLR6 KO mice compared to wild-type macrophages 
after RSV challenge (Figure 2.8).  CCL5 production in TLR4 KO was lower compared to 
wild-type cells but was higher compared to TLR2 KO or TLR6 KO macrophages 
(WT>TLR4 KO>TLR2 KO and TLR6 KO).   
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Figure 2.7  TLR2 and TLR6 mediate inflammatory cytokine production in response to 
RSV 
 
 
 
 
 
Figure 2.7 legend 
 
 
Macrophages were harvested from wild type, MyD88 KO, and TLR KO mice and were 
stimulated with RSV (0.3 MOI) or medium control for 24 hours.  Culture supernatants 
were harvested and tested for IL-6 production using ELISA.  Error bars are +/- SD.   
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Figure 2.8  TLR2 and TLR6 mediate chemokine production in response to RSV 
 
 
 
 
 
 
 
 
Figure 2.8 TLR2 and TLR6 mediate chemokine production in response to RSV 
 
Macrophages were harvested from wild type, MyD88, and TLR KO mice and were 
stimulated with RSV (0.3 MOI) or medium control for 24 hours.  Culture supernatants 
were harvested and tested for CCL2 and CCL5 production using ELISA.  Error bars are 
+/- SD.  
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Furthermore, MyD88 KO mice exhibited decreased production of each cytokine and 
chemokine assayed in response to RSV.  Since MyD88 is essential for TLR2, TLR6, and 
partially for TLR4 signaling, these data supports the hypothesis that TLR-driven  
MyD88-dependent signaling was important for early cytokine and chemokine production 
in response to RSV.  
 Next, type I IFN responses to RSV in TLR KO mice were examined.  RSV 
induced similar levels of type I IFN in the wild type-mice compared to each TLR KO 
group (Figure 2.9).  Poly I:C (TLR3 ligand) has been shown to stimulate type I IFN 
production independent of TLR1,2,4,6 (175).  RSV-induced type I IFN production was 
similar to Poly I:C-induced type one interferon production in wild type and TLR KO 
mice.  LPS has also been shown to induce type I IFN production albeit to a lesser extent 
than Poly I:C.  As expected wild type and TLR 1,2,6 KO mice produced equivalent 
amounts of type I IFN to LPS, while TLR4 KO did not respond to LPS.  This data 
suggests that RSV induces type I IFN production independent of TLR2 and TLR6 
signaling.   
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Figure 2.9  TLR2 and TLR6 are not involved in type I interferon production following 
RSV recognition 
 
 
 
 
Figure 2.9  TLR2 and TLR6 are not involved in type I interferon production following 
RSV recognition 
 
Macrophages were harvested from wild-type, TLR1, TLR2, TLR4 and TLR6 KO mice. 
Macrophages were stimulated with RSV (2 MOI), Poly I:C ( TLR 3 ligand, 50 ug/ml), 
LPS (TLR 4 ligand,100 ng/ml), or medium alone for 24 hours.  Harvested supernatants 
were tested for type I interferon production.  
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Discussion 
 
Activating host immune responses during RSV infection is dependent on complex 
signaling events initiated in part by TLRs.  These coordinated signaling events promote 
the production of cytokines, chemokines, and IFN !, $, and # that ultimately dictate the 
type of inflammatory environment (Th1 or Th2) in the lung.  Interestingly, the type of 
inflammatory environment generated during these early signaling events likely alters 
subsequent Th responses because susceptible infants exhibit skewed Th2 responses (12).  
Since recent findings have implicated TLR-mediated inflammation as potentially 
involved in the immunopathogenesis of RSV disease, emphasis has been placed on 
understanding how TLRs can influence immune responses against RSV (9, 16, 90, 125, 
140, 165).    
Initial studies conducted by Kurt-Jones et al. used C57BL/10ScNCr strain (TLR4 
mutant due to a deletion mutation) to examine the interactions between RSV and TLR4.  
However, during the final publication review, the strain designation was changed to 
C57BL/10ScCr (TLR4-deficient and IL-12 deficient), an error that was not caught by 
Kurt-Jones et al. during revision (unpublished).  Nevertheless, the authors demonstrated 
that intranasal (i.n.) infection of RSV in the TLR4 mutant mice resulted in delayed viral 
clearance at 10 days post infection compared to wild-type mice.  In a follow-up study 
published by the same group, Haynes et al. again used the C57BL/10ScN mice (TLR4-
deficient) to confirm their original findings (71).  Importantly, Haynes et al. indicated in 
the text that “C57BL/10ScNCr strain is homozygous for a null mutation of the TLR4 
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gene…a related mouse strain, C57BL/10ScCr (not used in these studies), has a reported 
defected in interleukin 12 (IL-12)-induced production of gamma interferon (IFN-#)…The 
C57BL/10ScN mice used in the present study were IL-12 responsive and expressed IFN-
# at levels similar to those of the wild-type.”  In contrast to these studies other 
investigators examined the perceived interaction between TLR4 and paramyxoviruses, 
including RSV, PMV, and Sendai virus, and found no association.  Briefly, Ehl et al. 
investigated whether deficiencies in TLR4, or deficiencies in IL-12R, could contribute to 
RSV susceptibility in the C57BL/10ScCr mouse (45).  The authors concluded that 
increased susceptibility to RSV in this mouse model was due to defects in IL-12R rather 
than defects in TLR4.  Second, studies by Van der Sluijs et al. explored the possible 
interaction between Sendai virus and TLR4 using C3H/HeJ (TLR4 mutant) mice (166).  
In summary, the authors were unable to find evidence of an interaction between Sendai 
virus and TLR4.  Furthermore, studies by Faisca et al. examined the interaction between 
pneumonia virus of mice (PVM), a member of the pneumovirus genus, and TLR4 using 
TLR4 mutant mice (46).  Since RSV and PVM share many similarities the authors 
suggested that the responses to both pathogens in the mouse should be similar.  
Additionally, the authors indicated that PVM is a natural mouse pathogen while RSV is 
not suggesting that PVM would be a more suitable model for examining TLR4 and 
pneumovirus interactions in the mouse.  In summary, the authors concluded that there 
was no evidence of an interaction between TLR4 and PVM.  Collectively, these studies 
seemed to suggest that some members of the paramyxoviridae family, including Sendai, 
PVM, and RSV, do not interact with TLR4 to activate innate immune responses.   
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However, data briefly summarized below suggest that RSV does indeed interact with 
TLR4 to promote innate immune activation.  
Following the Kurt-Jones et al. and Haynes et al. observations, Haeberle et al. 
used C3H/HeJ mice (TLR4 point mutation leading to LPS unresponsiveness) and 
demonstrated that NF-"B activation by RSV in vivo involves TLR4 (61).  Additionally, 
studies by Boukhvalova et al. in cotton rats establish that the formalin-inactivated vaccine 
strain of RSV stimulates a Th2-like response and this effect can by blocked using TLR4 
antagonists (16).  Furthermore, studies by Vogel and colleagues demonstrate a clear 
linkage between RSV disease in high- risk infants and particular TLR4 polymorphic 
alleles suggesting that TLR4 plays a significant role in RSV pathogenesis in humans (9).  
Interestingly, Rassa et al. demonstrated that MMTV, a murine retrovirus, also activated 
innate immunity via TLR4 (137).  Therefore, literature published by several different 
groups seems to indicate an important role for TLR4 in the activation of innate immunity 
in response to RSV infection.  Herein we have outlined some important factors that could 
highly affect study outcomes.  First, different inbred mouse strains do express different 
levels of baseline and induced TLR, including TLR4 that could likely contribute to 
differences in innate and acquired immune activation.  Importantly, C57BL/10ScN, 
C57B10/ScCr and C57BL/6 are distinct mouse strains that possibly differ in TLR 
expression.  Once TLR4 is activated, Macrophages and DCs start producing a variety of 
soluble factors that direct T helper cell differentiation
 
and activation of innate and 
adaptive immune pathways in a fashion that is not completely understood.  Second, the 
dose of RSV administered can influence disease outcome because high inocula of RSV 
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are required to elicit immune activation in mice.  Third, frozen RSV stocks have been 
shown to lose a substantial amount of activity over time (> 6 months). Therefore, it is 
critical to use recently propagated stocks for in vivo experiments to ensure optimum 
immune activation in mice.  Fourth, the cell lines in which RSV is propagated can greatly 
affect infectivity.  For example, studies by Taylor et al. have shown that genetically 
similar mice infected i.n with equivalent titers of RSV isolated from different cell lines 
show significant differences in the amount of virus recovered from the lungs (160).  
Collectively, differences in these parameters could influence experimental results 
between investigators.    
 The present study used C57BL6/J mice that lacked the TLR4 gene (TLR4 KO), 
and data presented here supports our original observations, further suggesting a role for 
TLR4 mediated innate immune activation in response to RSV, e.g., TLR4 deficiency 
blunted the cytokine response to RSV infection.  Additionally, we extended our initial 
observations by demonstrating that TLR2 signaling can also activate innate immunity in 
response to RSV. 
Studies presented here also provide evidence for direct interactions between RSV 
and TLR2 and TLR6, but not TLR1.  These findings are important because the lung 
cytokine and chemokine milieu is thought to directly shape cellular processes within the 
lung that prevent or promote RSV-induced disease (12).  Macrophages from TLR2 and 
TLR6 KO mice exhibited decreased production of TNF-! in vitro.  TNF-! has been 
linked to both viral clearance and exacerbated airway disease, suggesting one mechanism 
by which the characteristics of the immune response might dictate disease outcome.  In 
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fact, previous work indicates that RSV does indeed modulate TNF-! secretion, i.e. the 
small hydrophobic (SH) protein inhibits TNF-! secretion (51).  RSV likely inhibits a 
major inflammatory component of TLR2 signaling by limiting TNF-! signaling.  
Additionally, recent findings suggest that TNF-! can modulate TLR2 expression.  
Therefore, it is possible that RSV could further alter immune activation by limiting TLR2 
expression (157).  Signaling through TLR2 and TLR6 controlled expression IL-6, an 
important inflammatory mediator that is linked to RSV pathology (104).  In a model of 
airway allergic inflammation, TLR2 engagement can induce IL-6 production in response 
to mycoplasma and the lack of IL-6 production was associated with impaired bacterial 
clearance (174).  Therefore, TLR2-dependent IL-6 production, in conjunction with TNF-
!, may play a key role in mediating viral clearance.    
 TLR2 and TLR6 signaling promoted production of chemokines CCL5 and CCL2.  
Both chemokines are linked to RSV pathogenesis (35, 122, 161). CCL5 is produced 
primarily by Th1 polarized cells and can influence both innate and acquired leukocyte 
migration (95).  CCL2 functions as a potent chemotaxic molecule for monocytes, 
including neutrophils, and can influence Th polarization towards Th2 by stimulating IL-4 
production in T cells (60).  In fact, recent studies associate increased CCL2 production 
with skewed Th2 responses in RSV G primed BALB/c mice.  However, this study did not 
address whether CCL2 causes or results from a Th2 polarized inflammatory environment 
(35).  It is likely that CCL2 can influence Th2 polarization, as mice deficient in CCL2 
cannot mount strong Th2 responses (60).  Interestingly, studies by Liu et al. demonstrate 
a role for TLR3 and RIG-I in mediating IFN-$ production and NF-"B/RelA transcription 
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by lung epithelial cells in response to RSV (100).  Furthermore, our studies indicated that 
TLR2 and TLR 6 signaling was important for NF-"B dependent cytokine and chemokine 
production but not type I IFN production, suggesting that activation of innate immunity 
occurs via multiple TLRs in response to RSV to provide optimum protection against 
RSV-induced disease.  In light of the finding presented here it is possible that defects in 
TLR2 signaling could bias responses towards Th2 cytokine and chemokine responses in 
genetically susceptible individuals.  Our in vitro studies examined the early inflammatory 
response initiated by peritoneal macrophages in response to RSV.  Additionally, Suzuki 
et al. demonstrated that murine alveolar macrophages and peritoneal macrophages 
express similar levels of TLR2 and respond equally to TLR2 ligands, suggesting that 
alveolar macrophages and peritoneal macrophages likely exhibit similar responses to 
RSV(155).  Lung epithelial cells express TLR2 and may produce additional inflammatory 
components that further contribute to the early inflammatory environment (8, 154).  
Collectively, these findings suggested that control of cytokine and chemokine production 
by TLR2 is likely critical for supporting viral clearance while limiting RSV-induced 
disease. 
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Chapter III 
Introduction 
 
 In the previous chapter we described a role for TLR2 and 6, but not TLR1 in 
propagating innate immune signals following RSV recognition.  In this chapter we 
extended these findings by examining the role of TLR2 and TLR6 in controlling RSV 
replication.  Furthermore, we examined the role of these TLR in activating DCs and the 
consequences of abrogated TLR2 and TLR6 signaling on the recruitment of innate 
leukocytes, including neutrophils, into the lungs of RSV-infected mice.  Herein, these 
findings confirmed a physiological role for TLR2 and 6 signaling in the clearance of RSV 
from the lungs.  Furthermore, TLR2 and 6 signals were also involved in DC maturation 
and the early recruitment of neutrophils into the lungs.  Thus these data suggest TLR2/6 
signals are important for modulating pro-inflammatory responses against RSV.  This also 
suggests that TLR2/6 signaling may play a critical role in determining disease 
susceptibility following natural RSV infection.   
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Results 
 
RSV replication in TLR KO mice 
To examine the role of TLRs in RSV replication after in vivo infection, C57BL/6, 
TLR2 KO, TLR4 KO, and TLR6 KO mice were infected by intranasal (i.n.) instillation of 
2.4 x 10
6
 PFU/mouse of RSV.  Lungs were harvested four days after infection and virus 
levels were determined by immunoplaque assay.  Kinetic studies examining the day of 
peak virus titer in RSV resistant C57BL/6 as well as RSV permissive BALB/c and semi-
permissive B6.129F2/J mice indicated virus titer peaked at day 4 in all strains tested 
(Table 2.1).  These findings were in agreement with previous studies that demonstrated 
peak viral titer in mouse models occurs approximately 4 days after infection (152).  
Importantly, data summarized in Table 2.1 and previous studies have shown that wild- 
type C57BL/6 mice readily cleared RSV, resulting in significantly diminished virus 
recovery compared to more susceptible mouse strains such as BALB/c even at the day of 
peak viral load, day 4 post-infection (152).   
 Although the TLR KO mice were back-crossed onto the resistant C57BL/6 
background, RSV was readily recovered from the lungs of TLR2, TLR4, and TLR6 KO 
mice.  A significantly higher peak viral load was observed in TLR2 KO and TLR6 KO 
mice compared to wild type mice on the C57BL/6 background (Figure 3.1).  These data 
also indicated a significant difference in peak viral titer between TLR4 KO mice and 
C57BL/6 wild-type mice with higher viral loads in TLR4 KO mice.  These findings 
confirm our original observations using mice with deficiencies in TLR4 on the C3H and  
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Figure 3.1  RSV replication in TLR KO mice 
 
 
 
 
 
Figure 3.1 RSV replication in TLR KO mice 
 
Wild type (n=8), TLR4 KO (n=8), TLR2 KO (n=6), and TLR6 KO (n=4) mice were 
infected by intranasal inoculation with RSV A2 strain (2.4 x 10
6 
PFU/mouse).  Lungs 
were harvested 4 days after infection and plaques were enumerated using a Vero cell 
immunoplaque assay described in materials and methods.  Titer is represented as log10 
PFU/gram of lung tissue.  Solid lines represent the mean 1og10 for each group. Error bars 
are +/- SEM.  Note:  Mice that were negative for RSV by plaque assay were scored at 0.5 
times the lower limit of detection. 
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the C57BL/10 genetic backgrounds, which indicated that TLR4 was involved in RSV 
clearance (90).  Significantly higher virus titers in TLR2 KO and TLR6 KO lungs suggest 
an important role for TLR2 and TLR6 in controlling RSV replication in vivo.  
 
TLR2 signals promote neutrophil recruitment and DC activation in response to 
RSV 
To examine a possible role for TLR2 in the production of early inflammatory 
mediators in wild-type vs. TLR2 KO mice in response to RSV, wild-type C57BL/6, 
TLR2 KO, and MyD88 KO mice were infected, i.n., with 2.4 x 10
6
 PFU/mouse of RSV.  
Uninfected groups of each were used to control for lung cytokine production and 
leukocyte infiltrate.  Whole lungs and bronchoalveolar lavage (BAL) were collected at 
24, 48, and 96 hours post-infection. Total cellular CCL2 levels were measured from lung 
homogenates, since CCL2 is produced following TLR2 activation.   A significant 
decrease in CCL2 was observed in TLR2 KO compared to wild-type lungs at 24 hours 
post-infection (Figure 3.2).  CCL2 was undetectable at 48 and 96 hours post-infection in 
all groups (data not shown).  MyD88 KO mice did not produce detectable levels of CCL2 
compared to wild-type.  Although uninfected mice produced detectable basal levels of 
TNF-!, IL-6, and CCL5, we were unable to observe differences in cytokine and 
chemokine production in lung homogenates between groups (data not shown).  This data 
suggested TLR2 signaling is involved in early CCL2 production within the lungs of RSV 
infected mice. Since CCL2 is a potent leukocyte chemoattractant, the early recruitment of 
leukocytes to the lung following RSV infection  
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Figure 3.2  TLR2 signaling promotes CCL2 production in vivo 
 
 
 
 
 
Figure 3.2 TLR2 signaling promotes CCL2 production in vivo 
 
Wild-type, TLR2 KO, and MyD88 KO mice were infected by intranasal instillation with 
RSV A2 strain (2.4 x 10
6
 PFU/mouse).  Uninfected mice (n=3) were used to control for 
lung cytokine production. Lung tissue was harvested 24 hours post-infection.  Tissues 
were homogenized and tested for CCL2 production by ELISA (Wild type and TLR2 KO, 
n=7) (MyD88 KO, n=6).  Data are represented as pg/gram of lung tissue.  Solid lines 
represent the mean for each group. Error bars are +/- SEM. 
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was studied.  A large neutrophil (7.4
+
-F4/80
-
) influx was observed in the BAL of wild- 
type mice at 24 hours post-infection.  In contrast to wild-type mice, fewer neutrophils 
were observed in TLR2 KO mice BAL at 24 hours post-infection suggesting that TLR2 
signaling induced neutrophil migration into RSV infected lungs (Figure 3.3).  
Furthermore, low levels of neutrophils were detected in the BAL of wild type and TLR2 
KO mice at 48 hours post-infection and were undetected in BAL at 96 hours post-
infection suggesting neutophil migration occurs very early during the innate immune 
response to RSV.  Neutrophils were undetected in uninfected mice indicating RSV 
infection was necessary to induce neutrophil migration into the lung.   
Additionally, a reduced number of activated DCs (CD11
hi 
CD11b
hi
 CD86
+
) was 
observed in the BAL of TLR2 KO mice compared to wild type DCs at 24 and 48 hours 
post-infection (Figure 3.4).  MyD88 KO mice exhibited a reduced number of neutrophils 
and activated DCs in response to RSV infection, further indicating a role for TLR2 
dependent signaling in activating innate immunity against RSV.  Additionally, T cell, NK 
cell, and eosinophil migration into the BAL of wild-type vs. TLR2 KO mice was 
examined.  These cell populations were detected in the BAL at very low frequencies, and 
no differences were observed between the groups (data not shown).    
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Figure 3.3  TLR2 signals promote neutrophil influx following RSV infection 
 
 
 
 
 
 
 
 
Figure 3.3  TLR2 signals promote neutrophil influx following RSV infection 
 
Wild-type, TLR2 KO, and MyD88 KO mice were infected by intranasal inoculation with 
RSV A2 strain (2.4 x 10
6
 PFU/mouse).  Uninfected mice (n=3) were used to control for 
BAL infiltration.  24, 48, and 96 hours after infection, BAL were harvested from mice.  
BAL from each group (n=3 per group) was pooled and neutrophils were enumerated by 
flow cytometry.  Neutrophil (7.4+-F4/80-) populations are indicated as % positive cells 
of total gated cells. 
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Figure 3.4  TLR2 signals promote DC maturation in response to RSV 
 
 
 
 
 
 
 
Figure 3.4  TLR2 signals promote DC maturation in response to RSV 
 
Wild-type, TLR2 KO, and MyD88 KO mice were infected by intranasal inoculation with 
RSV A2 strain (2.4 x 10
6
 PFU/mouse).  Uninfected mice (n=3) were used to control for 
BAL infiltration.  24, 48, and 96 hours after infection, BAL were harvested from mice.  
BAL from each group (n=3 per group) was pooled and activated DCs were enumerated 
by flow cytometry.  DC (CD11b+-CD11c+-CD86+) populations are indicated as % 
positive cells of total gated cells. 
 
 
 
 
 
Discussion 
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Data presented in this chapter confirmed a role for TLR2/6 mediated innate 
signaling in controlling virus replication because TLR2 KO and TLR6 KO mice were 
less effective in controlling viral replication than wild type controls.  Interestingly, data 
presented in chapter II, indicating equivalent type I IFN responses between TLR KO 
strains compared to control mice, suggests early NF-"B-derived inflammatory mediators 
may be more critical in controlling virus replication in mouse lungs than type I IFN.  
Data suggesting TLR3 KO mice can control RSV replication similar to wild-type mice 
further supports this hypothesis.  One possible explanation is that lowered secretion of 
macrophage derived TNF-! in these mice decreased the host response and subsequently 
affected viral clearance.  TLR2 signaling was examined in vivo by infecting TLR2 KO 
mice with RSV.  We were unable to detect differences in TNF-!, IL-6, and CCL5 
production in vivo at 24 hours post infection suggesting peak production of these factors 
may have occurred at an earlier time point during the response.  However, this does not 
exclude the possibility that these mediators could play an important role in limiting virus 
replication at earlier time points (i.e. <24 hours) during infection since each has been 
shown to plays an important role in inflammation.   
TLR2 signaling did mediate CCL2 production in vivo.  Interestingly, studies 
examining acute sepsis peritonitis using mouse models showed that CCL2 production 
was indirectly involved in neutrophil influx through the production of leukotriene B4, 
suggesting that CCL2 production can influence neutrophil migration (105).  Moreover, 
we observed a decrease in lung neutrophils in the bronchoalveolar lavage of TLR2 KO 
mice at 24 hours post-infection.  These findings indicated that TLR2 mediated CCL2 
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production might be important for early neutrophil migration to the lung in response to 
RSV infection.   
Neutrophils are innate leukocytes that traffic to sites of infection via chemokine 
gradients and greatly aid clearance of virally infected cells.  The presence of neutrophils 
correlates with RSV-disease severity and, further, these cells secrete inflammatory 
mediators including reactive oxygen species and cytokines (i.e. IL-8) that further drive 
inflammation and indiscriminately kill both infected and uninfected tissues (11, 80, 167, 
168).  Therefore, heightened TLR2 signaling may mediate neutrophil associated airway 
inflammation through CCL2 production.   
Early inflammatory components can profoundly influence DCs ability to shape 
innate and acquired immune responses.  Therefore, we examined the affect of TLR2 
signaling on DCs activation.  Within the lung, immature DCs sense viruses including 
RSV in part through TLR and can promote either Th1 or Th2 T and B cell responses after 
receiving activation signals from components that make up the inflammatory 
environment (42, 75).  We observed a decrease in activated lung DCs (CD11b
hi
 CD11c
hi
 
CD86
+
) in TLR2 KO mice at 24 and 48 hours post-infection, suggesting TLR2-mediated 
signals generated during RSV infection could influence DC activation.  Interestingly, 
Rudd et al. showed that a lack MyD88 dependent signaling in DCs can promote Th2 
responses after RSV infection (140).  Since DCs can express TLR2, it is tempting to 
speculate that TLR2 signaling may contribute to Th2 polarizing DCs in response to RSV.  
Additionally, TLR2 signaling may further contribute to RSV responses by facilitating 
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interactions between DCs and neutrophils that can further shape T and B cell polarization 
(110).   
 Collectively, these studies indicated TLR2 in addition to previously discovered 
TLRs including TLR3, TLR7, and TLR4 plus CD14 activate innate immune responses 
upon RSV recognition (90, 141, 142).  TLR2 and TLR6 but not TLR1 signaling activated 
inflammatory components that are thought to promote clearance of RSV and prevent 
RSV-induced disease.  Since the early inflammatory environment greatly shapes 
subsequent immune responses, these findings provide new insight into how TLR 
signaling could contribute to a beneficial anti-RSV immune response.  Interestingly, 
TLR4 signaling can influence TLR2 expression following certain stimuli, suggesting the 
optimal induction of multiple signaling pathways may be required to elicit protective 
rather than deleterious innate immune responses following RSV infection, consistent with 
a role for both TLR4 and TLR2 in the response to RSV (48).   
 Finally, data presented in Chapters II and III suggested that TLR2 signaling was 
involved in activating Th1-like responses.  Therefore, RSV vaccines incorporating TLR2 
adjuvant may help elicit strong Th1 responses.  This strategy was evaluated in mouse 
models of RSV disease using the TLR2 ligand peptidoglycan as an adjuvant and showed 
effectiveness in limiting RSV-induced disease (66).  Alternatively, TLR2 antagonist 
therapies may provide some benefit to susceptible children during active infection by 
dampening inflammation and limiting neutrophil associated airway inflammation.  In 
light of the findings presented here, therapies targeting TLR2 signaling may prove 
beneficial in limiting RSV infection and preventing RSV-induced disease. 
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Chapter IV 
Preface 
 
 This chapter contains information relating to the construction, expression, of 
quantification of VLP-H/G and the use of VLP-H/G as a vaccine against RSV in mice.  
Dr. Trudy Morrison and her lab generated the data pertaining to construction, expression, 
and quantification of VLPs.  Dr. Morrison’s laboratory also conducted antibody titration 
assays.  I contributed to the execution of the vaccine study by growing RSV, infecting 
mice, harvesting tissues and blood, running virus plaque assays, performing CTL assays, 
preparing tissues for histology, scoring tissue sections, running statistics, and preparing 
manuscript for publication.   
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Introduction 
 
 RSV remains a high priority for vaccine development.  However, no licensed 
vaccines are available for use.  Monoclonal antibody therapy can be beneficial in high-
risk infants, but this treatment is cost-prohibitive for the general population.  While the 
overall goal for any vaccine is to induce protective immune responses in the recipient, 
any potential RSV vaccine must not only elicit strong, protective immune responses but 
also must protect against enhanced disease seen with early vaccine trials that 
demonstrated disastrous results following immunization with formalin-inactivated RSV.  
Despite numerous strategies aimed at combining efficacy and safety into a potential RSV 
vaccine, this successful combination has remained elusive.  In this chapter we describe a 
novel approach to create a potential RSV vaccine using virus-like particle (VLP) 
technology (Figure 4.1).  This platform has been used to successfully generate vaccines 
against HPV and HBV, and both vaccinations have proven to be safe and efficacious in 
humans.  Taking advantage of the antigenic nature of the RSV G protein, we have 
incorporated a G protein chimera into a VLP comprised only of the NDV M and NP 
proteins.  The data described here demonstrates that VLPs expressing RSV G (VLP-H/G) 
can elicit safe and protective responses in BALB/c mice and may be a promising 
candidate for a human vaccine.   
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Figure 4.1  Producing VLPs in vitro 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Producing VLPs in vitro 
 
This cartoon illustrates the formation of VLPs using cDNAs that encode viral proteins 
necessary for virus assembly.  The cDNAs encoding NDV NP and M along with a cDNA 
for a foreign antigen are transfected into cultured cells, and the nucleus transcribes the 
foreign DNA.  Cellular machinery assembles the VLPs that then bud from the cell 
surface forming infections particles that lack a genome.  The VLPs are quantified as 
described in the Materials and Methods and injected into hosts as a potential vaccine.   
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Results 
 
Construction and Expression of a NDV HN/RSV G protein chimera gene 
 To incorporate significant levels of RSV G protein into ND VLPs, the ectodomain 
of the RSV G protein was fused to the NDV HN protein cytoplasmic and transmembrane 
domains (Figure 4.2) to create a chimera H/G protein.  The sequences at the junction 
between the HN and G protein domains are shown in Figure 4.2 .   
The chimera protein was expressed in COS-7 cells and in avian cells and 
compared to the expression of the wild-type RSV G protein in transfected cells as well as 
the RSV G protein in RSV-infected Vero cell extracts (Figure 4.3).  The chimeric protein 
(lanes 1, 2, 5, and 6) was made in amounts similar to wild-type protein (lanes 3 and 7) 
and co-migrated with the wild-type protein made in transfected cells.  Both the wild-type 
and chimeric proteins were heterogeneous in size, indicated by the vertical lines on the 
left sides of each panel, a phenomenon likely due to inefficient glycosylation.  The 
heterogeneity also varied somewhat between monolayers, as illustrated in Figure 4.3, 
lanes 1, 2, 5, and 6.  Interestingly, the maximal sizes of both the wild type and chimera 
proteins varied with the cell type, as previously reported (52, 112). The G protein made in 
infected (or transfected, not shown) Vero cells (Figure 4.3, lane 9) as well as HEK 293T 
cells (not shown) migrated the slowest while the G protein or H/G chimera protein made 
in transfected COS-7 cells (Figure 4.3, lanes 1-3) (or HEp-2 cells, not shown) were 
slightly smaller.  The proteins expressed in avian cells (figure 4.3, lanes 5-7) were the 
smallest.   
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Figure 4.2  Constructing H/G chimera protein 
 
 
 
 
 
Figure 4.2  Constructing H/G chimera protein 
 
The diagram shows the locations of the cytoplasmic domain (CT), transmembrane 
domain (TM), and ectodomains domain of the NDV HN protein and the RSV G protein 
and the domains present in the NDV HN-RSV G chimeric protein (H/G).  Below the 
bars, the sequences at the junctions of the TM and ectodomains of the three proteins are 
shown. 
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Figure 4.3  Expressing H/G chimera protein in vitro 
 
 
 
 
 
Figure 4.3 Expressing H/G chimera protein in vitro 
 
Avian cells and COS7 cells were transfected with cDNAs encoding the  
proteins shown at the top of the figure.  Proteins present in extracts of cells at 48 hours 
post transfection or extracts from RSV infected cells (Marker) prepared after 4 days of 
infection were detected by Western analysis using a polyclonal anti-RSV antibody.  
Lanes 1-4, transfected COS 7 cell extracts, Lanes 5-8, avian cell extracts, Lane 9, RSV 
infected Vero cell extracts. 
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Incorporation of H/G chimera protein into ND VLPs 
 To determine the optimal combination of NDV proteins for the incorporation of 
the H/G protein into ND VLPs, avian cells were transfected with the H/G chimera protein 
cDNA and the NDV NP and M protein cDNAs and various combinations of the NDV F 
and HN protein cDNAs.  VLPs were purified from cell supernatants, and their protein 
content was determined by Western blots (Figure 4.4).  The NDV NP present in the VLPs 
is shown in the top panel while the bottom panel shows the H/G protein content.  Clearly, 
maximal incorporation of the chimera was achieved in the presence of only the NDV NP 
and M proteins.  Inclusion of the NDV F protein had little effect but, inclusion of HN 
protein inhibited incorporation of the chimera protein. 
Preparation of these VLPs for their use as an immunogen was accomplished by 
transient transfection of avian cells with the NDV NP, M protein and the H/G chimera 
protein cDNAs.  Particles released from these cells were purified as described in 
Materials and Methods.  The total protein content of the purified VLPs is shown by silver 
stains of polyacrylamide gels containing VLP proteins (Figure 4.5, left panel).  The silver 
stain indicated inclusion of the heterogeneous H/G protein, indicated by vertical bars 
alongside the panel.  The presence of the H/G protein was confirmed by Western analysis 
of the proteins in the purified VLPs (Figure 4.5, right panel).  We found that release of 
these particles from transfected cells was significantly enhanced by inclusion of heparin 
in the culture supernatant.  Since it is known that the RSV G protein binds to 
glycosaminoglycans (GAGs) (63, 64), we hypothesized that released VLPs with the RSV 
G protein ectodomain might rebind to GAGs on surfaces of cells, decreasing the 
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Figure 4.4  Incorporating H/G chimera protein into ND-VLP 
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Figure 4.4 legend 
 
Avian cells were transfected with cDNAs shown at the bottom of the panel (0.5  
!g/35mm plate).  VLPs in the supernatant were collected and purified as described in 
Materials and Methods.  Proteins in the particles were detected by Western analysis (WB) 
using anti-NDV (top panel) or anti-RSV (bottom panel).  The antibodies used do not 
detect NDV M protein.   HN, hemagglutinin-neuraminidase protein; F0, uncleaved NDV 
fusion protein; NP, NDV nucleocapsid protein; H/G, HN-G protein chimera.  
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Figure 4.5 Quantifying ND-VLPs expressing H/G protein chimera 
 
 
 
 
 
 
 
 
Figure 4.5  Quantifying ND-VLPs expressing H/G protein chimera 
 
Avian cells were transfected with cDNAs encoding the NDV M protein, NDV  
NP, and the H/G chimera protein, lanes 2, 3, 5, and 6, or with vector DNA only, lanes 1 
and 4.Heparin (10 !g/ml) was added to the supernatants of transfected cells as indicated 
at the top of the panel at 40 hours post transfection.  Particles in the supernatant were 
collected and purified as described in the Materials and Methods.  Proteins present in the 
particles were electrophoresed on polyacrylamide gels.  Lanes 1-3 show a silver stain of 
the proteins in the gel while lanes 4-6 show a Western blot (WB) of the gel using anti-
RSV to detect G protein sequences.  NP, NDV nucleocapsid protein; M, NDV membrane 
protein; H/G, HN-G protein chimera. 
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release of particles into the cell supernatant.  Peeples and colleagues have reported that 
heparin blocks infection with RSV (63).  Thus, we attempted to block the rebinding of 
released VLPs to cell surfaces by adding heparin.  Indeed, heparin significantly improved 
the recovery of VLPs containing the H/G protein (Figure 4.5, compare lanes 2 and 3 and 
lanes 5 and 6).    
 Densitometer analysis of silver-stained gels containing several preparations of 
VLP-H/G similar to that shown in Figure 4.5 and showed that the H/G protein 
represented from 15-20 percent of the total viral protein in these particles.  The amount of 
HN protein in ND VLPs is approximately 30 percent of the total viral protein.  Thus the 
efficiency of incorporation of the H/G chimera protein is slightly less than that of HN 
protein incorporation into VLPs. 
 
Murine Immune Responses to VLP-H/G  
 Antibody responses to the G protein delivered in VLPs were compared with those 
to the G protein in purified virus.  For this comparison, gradient-purified UV-inactivated 
RSV delivered by intraperitoneal inoculation, as well as infectious RSV delivered 
intranasally (I.N.) were utilized.  For comparisons with UV-inactivated RSV (UV-RSV), 
amounts of virus and VLPs that had comparable amounts of the G protein were utilized 
as immunogen. The concentrations of the G protein in VLP-H/G and UV-RSV were 
determined as described in Materials and Methods and the volumes of VLP-H/G 
preparation were adjusted so that the concentration of H/G protein was the same as the 
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concentration of G protein in virus.  The normalized preparations of UV-RSV and VLPs 
contained similar amounts of RSV G protein (Figure 4.6, compare lanes 5 and 6). 
 Mice (groups of 5) were immunized by intraperitoneal inoculation with 1, 3, 10, 
or 30 µg total VLP-H/G protein or comparable amounts of UV-irradiated, purified RSV 
or a single intranasal dose of infectious RSV.  Figure 4.7 indicates that antibody 
responses to G protein delivered by VLPs were somewhat better than G protein responses 
after UV RSV or infectious RSV immunization, when assayed using G protein made in 
COS7 cells as target antigen.  To explore this conclusion, the antibody titers in serum of 
mice immunized with the highest concentrations of antigen were determined by serial 
dilution of the serum using as target antigen G protein made in the human cell line HEK 
293T (Figure 4.8).  Figure 4.8 also shows antibody titers at day 42 after a boost of antigen 
at day 28.  For comparisons, the titers of serum after immunization with VLP-H/G, using 
as capture antigen G protein in purified RSV, are also shown.  The antibody titers to 
VLP-H/G increased with time and were similar to titers obtained after UV-RSV 
immunization.  Furthermore, titers in both sets of sera increased slightly with an antigen 
boost.  Thus, using different sources of target G protein with various amounts of 
glycosylation, the antibody levels obtained after intraperitoneal immunization with VLP-
H/G were as good as or better than levels obtained after immunization with inactivated 
RSV or infectious RSV. 
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Figure 4.6  VLP-H/G quantification for vaccine dosing 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 legend 
 
Vero cells were infected with RSV (MOI=1) and incubated for 4 days.  Virus was 
harvested and purified as described in Materials and Methods.  Increasing amounts of 
purified virus proteins were electrophoresed on polyacrylamide gels and resolved using 
Western blotting with an anti-RSV antibody as the probe (lanes 2-4).  Proteins in extracts 
from infected Vero cell extracts (IC) were included as marker proteins (lane 1).  Based on 
these results as well as silver stains (Figure 4.5), the concentration of VLP-H/G stock was 
adjusted such that the amount of G protein present was equivalent to the G protein in 
virus stocks.  Equivalent volumes of the VLP-H/G and virus stocks were electrophoresed 
on polyacrylamide gels and the G protein sequences detected using a monoclonal 
antibody specific to the G protein (lanes 5 and 6).  NP, RSV nucleocapsid protein; M, 
RSV membrane protein; F, RSV fusion protein, G, RSV G protein; H/G, HN-G protein 
chimera. 
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Figure 4.7  Antibody responses to RSV G protein in vaccinated mice (COS7 G target 
antigen) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7  Antibody responses to RSV G protein in vaccinated mice (COS7 G target 
antigen) 
 
 
Mice (groups of 5) were immunized by intraperitoneal inoculation of 0, 1, 3, 10, or 30 ug 
of total VLP-H/G protein or comparable amounts of purified UV inactivated RSV (UV-
RSV).  Another group of mice was immunized by intranasal inoculation with 3 X 10
6
 pfu 
of infectious virus/mouse. Serum was collected at 14, 21, and 28 days post immunization.  
Antibody present in a 1:100 dilution of each serum sample was detected by ELISA assay 
as described in Materials and Methods using as target antigen proteins present in COS 7 
cells transfected with cDNA encoding the RSV G protein.  The panel shows the average 
OD for each group of mice. The standard deviation within each group is indicated by the 
vertical line. 
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Figure 4.8  Antibody responses to RSV G following vaccination (I.P.) (HEK 293T G 
protein and purified RSV G protein target antigen) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8  Antibody responses to RSV G following vaccination (I.P.) (HEK 293T G 
protein and purified RSV G protein target antigen) 
 
Antibody titers in mouse serum samples collected 14, 21,or 28 days after immunization  
with 30 µg of total VLP-H/G protein (i.p.), UV-RSV protein (i.p.), or infectious RSV (3 x 
10
6
) (i.n) were determined by ELISA using serial dilutions of mouse serum. The titer was 
defined as the reciprocal of the dilution of sera that gave an OD of 3 fold over 
background.   Titers for individual mice are shown.  The mean is shown by a horizontal 
line and the standard deviation by the vertical line.   At 28 days post immunization, VLP-
H/G immunized mice were boosted with 10 µg VLP-H/G protein (i.p.), UV-RSV mice 
were boosted with 10 µg of UV-RSV protein (i.p.), and RSV mice were boosted with 
infectious virus (3 x 10
6
) (IN).  Antibody titers in serum samples obtained at 42 days after 
the initial immunization were also determined as described above. 
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Protection of Mice from RSV Replication after Intraperitoneal Immunization 
  
 To determine if the immune responses to VLP-H/G could protect mice from RSV 
challenge, BALB/c  mice, which had been immunized with 30 µg of total VLP-H/G 
protein and then boosted with 10 µg of total VLP-H/G protein, were challenged i.n. with 
infectious RSV.  As controls, mice previously infected with infectious RSV were 
challenged with a second dose of virus.   Another set of mice that had not received any 
immunogen, were also infected.  At 4 days post infection, the time previously determined 
to yield maximal virus titers (118), the virus titer in the lungs was determined.  Figure 4.9 
showed that virus was detected in the lungs of unimmunized mice, but no virus was 
detected in the lungs of mice previously immunized with VLP-H/G or, as expected, mice 
previously infected with live RSV.  Thus immunization with VLP-H/G protected mice 
from RSV replication in lungs. 
 
Intramuscular Immunization with VLP-H/G 
 Because immunization in humans is most often via inoculation intramuscularly 
(I.M.), the immune responses of mice to this route of VLP-H/G delivery were also 
determined.  Also included in these studies was formaldehyde-treated RSV (FI-RSV), 
which served as a positive control for abnormal immune responses to vaccine 
preparations previously described. A group of mice immunized I.N. with infectious RSV 
was also included.  I.M. immunization of 10 µg and particularly 40 µg of VLP-H/G 
protein resulted in detectable antibodies specific to the RSV G protein, levels that 
continued to increase up to 38 days (Figure 4.10).  In contrast to the results shown in  
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Figure 4.9  VLP-H/G vaccination (I.P.) protects mice from RSV replication in lungs 
 
 
 
 
 
 
Figure 4.9 VLP-H/G vaccination (I.P.) protects mice from RSV replication in lungs 
 
Groups of 5 BALB/c mice were immunized with infectious RSV (IN 3 x 10
6
 pfu/mouse), 
VLP-H/G (IP with 30 µg/mouse).  At 48 days post immunization, mice were boosted 
with RSV (IN with 3 x 10
6
 pfu/mouse) or VLP-H/G (IP with 10 mg/mouse).  After 12 
days, mice were infected by intranasal inoculation of infectious RSV (3 x 10
6
 
pfu/mouse).  Unimmunized control mice (5 animals) were infected with RSV (IN 3 x 10
6
 
pfu/mouse). Another group of unimmunized mice was left unchallenged.  After 4 days of 
infection, lungs were removed and virus in lung tissue was titered by plaque assay as 
described in Materials and Methods.  Titers shown for unchallenged mice are the limit of 
detection of virus. 
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Figure 4.10  Antibody responses to RSV G following vaccination (I.M.) (293T G protein 
target antigen) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 legend 
 
BALB/c mice (groups of 5) were immunized by intramuscular (I.M.) instillation of 10 or 
40 µg of total VLP-H/G protein. Another group of mice received FI-RSV by I.M. 
inoculation (equivalent of   5 x 10
6
  pfu/mouse). Control groups of mice received 
infectious RSV (1 x 10
6
 pfu/mouse by IN inoculation) or no immunogen. Serum was 
collected at 16, 21, 28, 38, and 51 days post immunization.  A boost (10 µg VLP-H/G, 1 
x 10
6
 pfu infectious RSV, or  5 x 10
6
  pfu equivalent of  FI-RSV) was delivered at day 38.  
Antibody present in a 1:50 dilution of each serum sample was detected by ELISA assay 
as described in Materials and Methods using as target antigen proteins from HEK 293T 
cells transfected with cDNA encoding the RSV G protein.  Panel shows the optical 
density (OD) for each sample.  The mean and the standard deviation within each group 
are indicated by the horizontal line and the vertical line, respectively. 
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Figure 4.7, immunization by I.N. inoculation of infectious RSV resulted in barely 
detectable levels of serum antibodies.  However, these mice received nearly three times 
lower amounts of virus than mice in the groups described in Figure 4.7.  Sera from mice 
immunized with FI-RSV also contained barely detectable levels of RSV G protein 
specific antibodies (Figure 4.10).    All antibody levels increased significantly following 
antigen boost and RSV challenge (Figure 4.10).   
To determine if immunization with VLP-H/G could stimulate RSV G protein- 
specific CTL responses, groups of mice were immunized with a single dose of 10 or 40 
µg total VLP protein intramuscularly.  Control mice received a single dose of infectious 
dose of RSV (I.N.).  A third group of mice received no immunogen.  After 35 days, 
spleens were harvested, stimulated in vitro with irradiated RSV-infected Vero cells, and 
CTL activity in these cultures was measured.  Spleen cells from both groups of VLP-H/G 
immunized mice exhibited significant CTL activity, activities comparable to that 
observed in spleen cells from RSV immunized mice (Figure 4.11).  Thus, VLP-H/G 
immunization stimulated robust CTL activity. 
 To determine the protective effects of IM immunization, mice that had received 
only one dose of immunogen were challenged with infectious RSV 38 days after 
immunization.  The titers of virus in lungs of these mice after 4 days of infection are 
shown in Figure 4.12.  Remarkably, mice immunized with a single dose of either 10 µg 
and 40 µg of total VLP-H/G protein were protected from virus replication, as were mice 
that had been previously infected with live RSV.   However, mice immunized with FI-
RSV were not protected from virus replication. 
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Figure 4.11  CTL responses following VLP-H/G vaccination (I.M.) 
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Figure 4.11 CTL responses following VLP-H/G vaccination (I.M.) 
 
CTL activities of mice immunized, I.N., with a single dose of infectious RSV, a single 
dose, I.M., of 40 µg of VLP-H/G protein, or 10 µg of VLP-H/G were determined as 
described in Materials and Methods. Spleens were harvested from mice 5 weeks post-
immunization. Percent of chromium release is indicated on the y-axis with different 
effector to target ratios (E:T) indicated on the x-axis.  Each panel compares CTL activity 
after immunization with CTL activity of non-immunized mice.   
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Figure 4.12  I.M. VLP-H/G vaccination protects from RSV replication in mouse lungs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12  I.M. VLP-H/G vaccination protects from RSV replication in mouse lungs 
 
BALB/c mice (groups of 5) were immunized by intramuscular (IM) inoculation of 10 or 
40 µg of total VLP-H/G protein. Another group of mice received FI-RSV by IM 
inoculation (equivalent of   5 x 10
6
  pfu/mouse). Control groups of mice received 
infectious RSV (1 x 10
6
 pfu/mouse by IN inoculation).  After 38 days, all mice were 
challenged with infectious RSV (1.6 x 10
6 
pfu/mouse). One group of mice received no 
immunization and no RSV challenge.  Four days after infection, lungs were harvested 
and the virus titers were determined by plaque assay as described in Materials and 
Methods.  Titers shown for uninfected mice are the limit of detection of virus. 
 
 
 
 
 
 
 
Immunization 
Challenge None RSV RSV RSV RSV RSV 
None FI-
RSV 
VLP 
H/G 40 
mg 
VLP 
H/G 10 
mg 
RSV None 
RSV titer log10 
PFU/gram lung 
  
84 
Lung Pathology after RSV Challenge 
 A key property required of an effective RSV vaccine is the absence of abnormal 
immune responses upon challenge with infectious RSV (Figures 13-14).  In experiments 
utilizing intraperitoneal inoculation, lungs from each group of mice were examined for 
inflammation at 4 days post infection with RSV.  No excess inflammation was observed 
in mice immunized with VLP-H/G (not shown) when compared to mice immunized with 
infectious RSV based on hematoxylin and eosin (H&E) analysis of lung tissue.  To 
maximize any potential abnormal responses due to VLP immunization, mice immunized 
I.M. with 10 or 40 µg of VLP-H/G protein were boosted with 10 µg of VLP-H/G protein 
38 days after immunization, infected with RSV 7 days later, and then, lungs were 
harvested 6 days after infection.  Three control groups of mice, that is; mice that were 
unimmunized and unchallenged, mice subjected to a primary RSV infection, and mice 
immunized and then challenged with infectious RSV, were included.  Positive controls 
for abnormal responses were mice immunized with FI-RSV and then challenged with 
infectious RSV.  Figure 4.15 shows representative fields of lung sections from each 
group of mice stained with H&E.  Lungs from mice previously immunized with 
infectious RSV, mice with a primary RSV infection, and VLP-H/G immunized mice 
showed some influx of lymphocytes.  However, the FI-RSV mice showed massive influx 
of lymphocytes around both blood vessels and airways and in the interstitial spaces with 
formation of circumferential or near circumferential cuffs around blood vessels and small 
airways.  Lung sections from all mice were scored for inflammation around airways, 
blood vessels, and in interstitial spaces, and the results are shown in Figures 4.16-18,  
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Figure 4.13  Normal Mouse lung anatomy 
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Figure 4.13  Normal Mouse lung anatomy 
 
 
A representative H&E section of a naïve mouse lung is shown.  Lungs were harvested 
from mice as indicated in materials and methods and fixed for tissue embedding and 
immunohistochemistry.  A gross section of lung is depicted with highlighted areas 
expanded to show greater detail of indicated anatomical locations.     
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Fig 4.14  FI-RSV vaccination enhanced pathology in mouse lung  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14  FI-RSV vaccination enhanced pathology in mouse lung 
 
A representative H&E section of a FI-RSV immunized mouse lung following RSV A2 
infection as described in materials and methods is shown.  Lungs were harvested from 
mice as indicated in materials and methods and fixed for tissue embedding and 
immunohistochemistry.  A gross section of lung is depicted with highlighted areas 
expanded to show greater detail of indicated anatomical locations.    Note the heavy 
cellular infiltrate invading and surrounding tissues.  
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respectively.  While immunization with FI-RSV recapitulated previously documented 
abnormal histology of lungs after infectious virus challenge, the lungs from mice 
immunized with VLP-H/G did not show this abnormal pathology.  Rather, the 
inflammation scores for the VLP-H/G immunized mice showed no statistical differences 
from scores for mice immunized and then challenged with infectious RSV or mice 
subjected to a primary RSV infection.  In contrast, the differences between the scores of 
lungs from FI-RSV- and VLP-H/G-immunized mice were statistically significant. 
 The lung sections of FI-RSV immunized mice also showed abnormal cells lining 
airways consistent with increased intracellular mucous production (Figure 4.15, panel H) 
while cells lining airways of VLP-H/G immunized mice did not show this type of 
morphology (Figure 4.15, panel G).  To explore this observation, lung sections were 
stained with PAS to visualize material consistent with increased mucous production.  
Representative sections of VLP-H/G immunized mice and FI-RSV mice as well as 
control mice are shown in Figure 4.19.  These sections were scored for the percent of 
airway linings showing PAS positive staining and the results are shown in Figure 4.20.  
VLP-H/G immunized mice showed significantly less PAS staining than the FI-RSV 
immunized mouse lungs (p= 0.0014).  Thus, comparisons of the lungs of RSV-challenged 
mice indicate that VLP-H/G-immunized mice do not show the abnormal pathology 
associated with the FI-RSV vaccine. 
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Figure 4.15  Mouse lung morphology after VLP-H/G vaccination 
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Figure 4.15  Mouse lung morphology after VLP-H/G vaccination 
 
Groups of BALB/c mice were immunized with infectious RSV (1 x 10
6
 pfu/mouse IN), 
10 µg VLP-H/G (IM) or 40 µg VLP-H/G (IM), boosted with the homologous antigen (1 x 
10
6
 pfu RSV/mouse or 10 µg of VLP-H/G/mouse) and challenged with RSV (2.88 x 10
6
 
pfu /mouse).  After euthanasia at day 51, lungs were prepared for tissue sections, as 
described in Materials and Methods, and stained with hematoxylin and eosin (H&E) 
(Panels A-H). Panel A:  no immunogen, no challenge; Panel B:  primary RSV infection; 
Panel C: RSV immunized mice challenged with RSV; Panel D: VLP-H/G 10 µg 
immunization and RSV challenge; Panels E, G: VLP-H/G 40 µg immunization and RSV 
challenge; Panels F, H: FI-RSV immunization and RSV challenge. All images were 
acquired using the same camera settings.  Images were adjusted for size and contrast 
using Adobe Photoshop, using the same settings for all images. 
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Fig 4.16  Statistical analysis of inflammation around mouse airways after VLP-H/G 
vaccination  
 
 
 
 
 
 
Figure 4.16  Statistical analysis of inflammation around mouse airways after VLP-H/G 
vaccination 
 
Lung tissue sections were harvested 6 days post-challenge as described in Materials and 
Methods. Tissues from each mouse were stained with H&E and 10 random blood vessels 
per mouse were scored blindly by a pathologist for inflammation on a scale of 0-3, as 
described in Materials and Methods.  Each data point represents the average of 10 blood 
vessels per mouse. Groups of mice are indicated at the bottom of the panels (ns, 
differences not statistically significant). 
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Figure 4.17 Statistical analysis of inflammation around mouse blood vessels after VLP-
H/G vaccination 
 
 
 
 
 
 
 
 
Figure 4.17  Statistical analysis of inflammation around mouse blood vessels after VLP-
H/G vaccination 
 
Lung tissue sections were harvested 6 days post-challenge as described in Materials and 
Methods. Tissues from each mouse were stained with H&E and 10 random airways per 
mouse were scored blindly by a pathologist for inflammation on a scale of 0-3, as 
described in Materials and Methods.  Each data point represents the average of 10 blood 
vessels per mouse. Groups of mice are indicated at the bottom of the panels (ns, 
differences not statistically significant). 
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Figure 4.18 Statistical analysis of inflammation around mouse interstitial spaces after 
VLP-H/G vaccination 
 
 
 
 
 
Figure 4.18  Statistical analysis of inflammation around mouse interstitial spaces after 
VLP-H/G vaccination 
 
Lung tissue sections were harvested 6 days post-challenge as described in Materials and 
Methods. Tissues from each mouse were stained with H&E and 10 random interstitial 
spaces per mouse were scored blindly by a pathologist for inflammation on a scale of 0-3, 
as described in Materials and Methods.  Each data point represents the average of 10 
blood vessels per mouse. Groups of mice are indicated at the bottom of the panels (ns, 
differences not statistically significant). 
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Fig 4.19  PAS staining of goblet cells in mouse airways 
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Figure 4.19  PAS staining of goblet cells in mouse airways 
 
 
Groups of BALB/c mice were immunized with infectious RSV (1 x 10
6
 pfu/mouse IN), 
10 µg VLP-H/G (IM) or 40 µg VLP-H/G (IM), boosted with the homologous antigen (1 x 
10
6
 pfu RSV/mouse or 10 µg of VLP-H/G/mouse) and challenged with RSV (2.88 x 10
6
 
pfu /mouse).  After euthanasia at day 51, lungs were prepared for tissue sections, as 
described in Materials and Methods, and stained with periodic acid-Schiff (PAS) which 
detects mucous produced by resident goblet cells. Panel A: no immunogen, no challenge; 
Panel B: primary RSV infection; Panels C: RSV immunized mice challenged with RSV; 
Panel D: VLP-H/G 10 µg immunization and RSV challenge; Panels E: VLP-H/G 40 µg 
immunization and RSV challenge; Panels F: FI-RSV immunization and RSV challenge. 
All images were acquired using the same camera settings.  Images were adjusted for size 
and contrast using Adobe Photoshop, using the same settings for all images. 
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Fig 4.20  Statistical analysis of goblet cells in VLP-H/G immunized mice 
 
 
 
 
 
 
 
 
 
Figure 4.20  Statistical analysis of goblet cells in VLP-H/G immunized mice 
 
Lung tissue sections were harvested 6 days post-challenge as described in Materials and 
Methods. Tissue sections stained with PAS were scored as the percent of 25 random 
airways positive for PAS stain.  Groups of mice are indicated at the bottom of the panels 
(ns, differences not statistically significant). 
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Discussion 
  
 Results presented here describe a novel vaccine candidate for respiratory syncytial 
virus, a virus-like particle that contains an RSV surface protein.  The approach takes 
advantage of the very efficient production of VLPs by the structural proteins of NDV 
(127).  The results presented here demonstrated, first, that the ectodomain of the RSV G 
protein could be incorporated into particles formed with the NDV NP and M protein and 
that these particles could be quantitatively produced.  Second, these VLPs, VLP-H/G, 
stimulated soluble immune responses specific to the RSV G protein and primed cytotoxic 
T lymphocyte responses.  Third, immunization of mice with two, or even a single dose of 
these particles, resulted in the protection of mice from RSV replication in lung tissue.  
Lastly, upon RSV challenge of VLP-H/G-immunized mice, there was no increased 
pathology in the lungs compared to lungs of mice immunized by natural infection. 
 
Generation of ND VLPs containing the RSV G Protein 
 While VLPs are increasingly being considered as vaccines, two have been 
licensed for use in humans (77), VLPs have not been explored as a potential RSV 
vaccine.  We chose to utilize ND VLPs as a platform for the presentation of RSV proteins 
in a VLP for several reasons.  First, only one study of the assembly of VLPs with RSV 
proteins has been published (162) and the requirements for their formation are relatively 
undefined.  Our preliminary studies showed that the release of RSV VLPs is significantly 
less efficient than release of ND VLPs (unpublished observations).  Second, ND VLPs 
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stimulate robust soluble and cellular immune responses and the antibody responses are 
neutralizing (Morrison et al., manuscript in preparation), indicating that these VLPs are 
potent immunogens.  In addition, since NDV is an avian pathogen (4), there is no 
preexisting immunity to NDV proteins in human populations.  Third, that RSV antigens 
could be incorporated into ND VLPs was suggested by results of our previous studies 
(Morrison et al, manuscript in preparation) of the requirements for assembly of ND 
VLPs.  Wild-type foreign glycoproteins can be incorporated into ND VLPs due to the 
phenomenon of phenotypic mixing (17), but at very low frequency (Morrison et al., 
unpublished observations).  However, specific, quantitative assembly of a glycoprotein 
requires only the cytoplasmic tail and transmembrane domains of an NDV glycoprotein, 
likely due to specific interactions with the core proteins (Morrison et al., manuscript in 
preparation).  Since both the NDV HN protein (106) and the RSV G protein (29, 172) are 
type 2 glycoproteins, we chose to make a chimera protein with the NDV HN protein CT 
and TM domains fused to the RSV G protein ectodomain.   
We have also reported that release of ND VLPs requires the M protein, and the 
efficient assembly of the NDV HN protein into ND VLPs requires both the NP and M 
proteins (127). Thus, our VLP-H/G particles were built using these two NDV proteins. 
Wild-type F protein has no negative or positive effect on incorporation of the chimera 
protein into VLPs.  Thus, we were able to eliminate it from these particles. Furthermore, 
we found that inclusion of the wild-type HN protein interferes with incorporation of the 
H/G chimeric protein, perhaps due to competition with the chimera protein for binding 
sites with either NP or M proteins or both. Thus this protein was also omitted.   
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Importantly, we demonstrated that yields of VLP-H/G particles were significantly 
enhanced in the presence of heparin in the media. Since the RSV G protein binds to 
glycosaminoglycans (63, 64), binding that can be inhibited by exogenous heparin, we 
sought to block rebinding of the released H/G protein containing VLPs to cell surfaces by 
inclusion of heparin.  Indeed, heparin significantly increased the efficiency of recovery of 
particles in the cell supernatants.  This finding also strongly suggests that the H/G 
chimera protein retains the binding activity of the wild-type G protein. 
 
Immune responses to the RSV G protein upon immunization with VLP-H/G 
 As has been previously noted by others (112), we found that the maximal sizes of 
the RSV G as well as the H/G chimera protein varied with the type of cell in which they 
were expressed, a result likely due to cell type variation in the glycosylation.  
Importantly, the least glycosylated protein was produced in avian cells, and it was this 
cell type that was utilized to produce the VLPs.  However, the under-glycosylated protein 
stimulated antibodies that would bind to more heavily glycosylated protein present in 
transfected COS7 cells (Figure 4.7) or transfected HEK 293T cells (Figure 4.8).   The 
levels of these antibodies raised against the H/G protein were similar to or higher than 
levels of antibodies raised against comparable amounts of the more fully glycosylated G 
protein in UV-inactivated RSV using, as target antigen in ELISA, two different sources 
of target G protein (Figure 4.7-8). Thus, the lower levels of glycosylation in the VLP- 
associated H/G protein did not adversely affect the levels of anti-G protein antibodies 
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after immunization. Indeed, the under-glycosylated protein may be a better antigen, as the 
protein sequence may be more accessible. 
 Our results also showed that, while the VLP-H/G delivered by either 
intraperitoneal inoculation or intramuscular immunization resulted in antibody responses 
to the G protein, antibody levels increased faster and peaked sooner after intraperitoneal 
immunization than after intramuscular immunization.  The titers of antibodies after 
intramuscular immunization were also lower prior to a boost. Maximal titers after a single 
dose delivered IM were, on average, 100, in contrast to titers of, on average, 400 after IP 
immunization.  However, after an IM boost and RSV challenge, the IgG antibody levels 
after IM immunization increased significantly and to levels higher than that seen after 
boosts delivered by IP (compare Figure 4.8, and Figure 4.10).  Both routes of 
immunization were effective, however, since both routes of immunization resulted in 
inhibition of RSV replication upon challenge.  
 Data presented here demonstrated that VLP-H/G particles were also capable of 
eliciting strong CD8 T cell responses in immunized mice, levels similar to CD8+ T cell 
responses after virus infection.  This observation is in agreement with previous 
observations that other types of VLPs can stimulate CTL responses (20, 37, 126).  VLPs 
can likely promote CTL responses because viral antigens are displayed in highly 
repetitive, ordered arrays on particle surfaces, a presentation ideally suited for 
phagocytosis by resident leukocytes such as macrophages and DCs (38, 116, 126). 
However, as there is no clear-cut T cell epitope defined for the G protein, the specificity 
of the CTLs detected here is unclear.  Since it was only the G protein ectodomain that 
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was in common between the immunogen and the antigens used to stimulate spleen cells 
in culture, it seems most likely that VLP-H/G stimulated G protein specific T cells.  
Perhaps under glycosylation of the avian cell derived G protein unmasked a T cell 
epitope.  Alternatively, it is perhaps possible that the CTLs detected in these experiments 
may be due to some type of cross-reaction between the NP or M core proteins of RSV 
and NDV. However, there are no common short sequences in the RSV NP and M 
proteins and the NDV NP and M proteins. 
 
Protection provided by VLP-H/G immunization to RSV challenge 
The role of the RSV G protein in stimulating protective immune responses is not 
entirely clear.  Some G protein subunit vaccines with a sequence of the G protein induced 
protection in animals although some have resulted in enhanced lung pathology or short- 
lived responses. Viral vectored vaccines containing the G protein gene have been shown 
to be protective in some systems but not others (reviewed in (99)). DNA vaccines 
containing the G protein gene have demonstrated some protection (reviewed in (99)).  
However, in many cases, the mechanisms involved in protection observed are unclear. 
VLP-H/G immunization protected mice from RSV replication in murine lungs 
after intranasal challenge with infectious RSV.  Protection was observed after 
intraperitoneal immunization of 30 µg total VLP protein, followed by a boost of 10 µg.  
Protection was also observed after a single intramuscular injection of VLP-H/G.  In 
addition, protection was obtained after a single dose of 10 µg of total VLP-H/G protein, 
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an amount that corresponded to approximately 1.5 to 2 µg of G protein per animal.  Thus 
the VLP-H/G was a very potent protective immunogen. 
The mechanisms responsible for this protection are not yet clear. Soluble antibody 
may be involved.  However, the anti-G antibodies in the murine sera were not 
neutralizing in an in vitro plaque reduction assay (not shown).  These findings were in 
agreement with previously published literature suggesting that antibodies raised against 
RSV G can confer protection without being neutralizing (7, 153).  For example, BALB/c 
mice that prophylactically received anti-RSV G immunoglobulin were protected against 
live RSV challenge (70).   While the mechanisms underlying this phenomenon are not yet 
fully understood, some research has suggested Fc#R-dependent and independent 
mechanisms may explain the protective effects of the anti-RSV G antibody.  Fc-
dependence was shown by studies in which portions of the IgG heavy chain region were 
removed to create anti-RSV G light chain fragments (Fab’2).  Upon administration to 
mice, those receiving the IgG light-chain fragments were more susceptible to live RSV 
infection than mice receiving the wild-type IgG (111, 113).  Therefore, these studies 
suggest that the Fc portion of the anti-RSV G antibody can confer protection in naïve 
mice.     
Furthermore, it has been suggested that antibodies specific to the F protein are 
more important for protection than antibody to G protein (128).  While antibodies to G 
are not neutralizing in in vitro systems, it is possible that anti-G protein antibodies have 
an undefined role in preventing the spread of infection in the lung, a role unrelated to 
virus neutralization as measured by virus neutralization in vitro.  It is also possible that 
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cell-mediated immune responses have a role in protection. While no CD8 T cell epitopes 
have been described for the G protein, data presented here and in other studies suggest a 
role for G in establishing a cytotoxic CD8 T cell response (18, 47), although a potential 
mechanism for these responses has not yet been described.  In addition, recent results 
indicate that induction of innate immune responses are important for the development of 
potent B cell responses (50, 74, 93, 129) and for affinity maturation of antibodies, 
including anti-RSV antibodies (41).   
 
Enhanced disease after RSV challenge 
 Major complications to RSV vaccine development are the results of early vaccine 
trials using formalin-inactivated RSV as an immunogen.  This preparation, called lot 100 
(86), resulted in enhanced disease upon RSV infection, and the enhanced disease was 
characterized by heightened pulmonary cellular infiltrates and increased airway hyper-
reactivity indicative of Th-2 allergy-like responses (82, 125).  Enhanced disease has been 
mimicked in animal models, including BALB/c mice used here, and is characterized by 
an increased inflammation of respiratory tissue due to influx of lymphocytes and 
eosinophils, enhanced mucous secretion, and an unbalanced immune response (39, 119, 
125). Increased inflammation associated with FI-RSV immunization was reproduced here 
as indicated by increased numbers of immune cells around blood vessels, airways, and in 
interstitial spaces in FI-RSV immunized mice (Fig 4.15-4.17).  Airway hyperreactivity is 
often associated with a strong Th2-biased response and the presence of goblet cells.  
Goblet cells are implicated in disease pathogenesis because they can produce large 
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quantities of mucin, which contribute to airway obstruction, further worsening disease (2, 
43).   Previous studies have shown that RSV can induce goblet cells, a condition referred 
to as goblet cell hyperplasia (GCH), in the lungs of BALB/c mice and that Th2-sensitized 
mice exhibit extensive GCH following RSV infection (14, 15, 103).  Indeed, results 
presented here indicated that FI-RSV immunized mice, following RSV challenge, 
exhibited significant GCH, a metaplastic process resulting in near total replacement of 
epithelial cells by goblet cells, in most airways. 
Many studies over decades have sought to clarify the mechanisms for this 
enhanced disease.  Early reports suggested immunization with the purified G protein 
alone or vaccinia virus delivered G protein elicited an unbalanced, Th2-dominated 
immune response (59, 68, 124).  More recent studies suggest that the unbalanced 
response observed in these cases may be due to the soluble form of the G protein (sG), 
not the membrane bound form (mG) or to the method of antigen delivery (78, 79). It has 
been suggested that sG protein, which represents 80% of G protein released from cells 
(42, 79), can subvert host immune detection in part by inhibiting Toll-like receptor 3 and 
4 mediated IFN-$ production and that the Th balance can be restored using TLR 
adjuvants (66, 146).  It has also been suggested that disease enhancement is related to two 
mucin-like domains (GCRR) in the G protein ectodomain (GCRR) (56, 92). This GCRR 
domain includes a CX3C chemokine motif that has been hypothesized to affect leukocyte 
trafficking to lungs (69), indirectly promoting Th2 responses by inhibiting important 
immune pathways that support Th1 responses.  In contrast, it has been suggested recently 
that enhanced disease caused, at least by formalin-inactivated RSV vaccines or any 
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nonreplicating vaccine, is not due directly to the G protein.  Rather, it was suggested that 
these immunogens are poor activators of innate immunity and, as a result, fail to 
stimulate a strong acquired immune response (41).  
To determine if VLP-H/G immunization stimulated symptoms of enhanced 
disease in mice, inflammation of the lungs of immunized and challenged mice were 
scored as previously described (114), and airways were scored for goblet cell hyperplasia. 
There were no statistically significant differences between VLP-H/G and infectious RSV 
immunized mice. Thus, the VLP-H/G did not induce increased pulmonary inflammation 
and GCH compared to natural infection.  In contrast, the FI-RSV immunized mice 
showed dramatic inflammation that was statistically very significantly different from that 
observed for VLP-H/G immunized mice.  FI-RSV-immunized mice also displayed 
dramatically increased GHC that was significantly enhanced over that observed in the 
VLP-H/G or RSV immunized mice. These results suggest that a VLP vaccine strategy 
may not predispose animals to enhanced RSV induced disease upon challenge and that 
the ectodomain of a particle associated G protein does not directly result in enhanced 
disease. 
 In sum, many of our results demonstrated that the RSV G protein ectodomain was 
efficiently incorporated into virus-like particles based on NDV proteins and that these 
particles stimulated very effective immune responses in mice, immune responses that 
prevented replication of RSV in lung tissue.  Furthermore, these particles did not result in 
enhanced pulmonary inflammation typified by FI-RSV or UV-RSV. 
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Chapter V 
Conclusions and Future directions 
 
 RSV continues to pose a serious global health threat, but efforts to limit this 
pathogen are handicapped by the limited understanding of the virus itself and the 
mechanisms by which it induces disease in humans.  While the cytopathic effects of RSV 
infection in lung tissue can play a role in the etiology of RSV-induced disease, a growing 
body of evidence suggests that host immune responses, induced following infection, are 
major contributors to disease susceptibility.  While research aimed at understanding how 
both innate and acquired immune responses could contribute to disease susceptibility 
have provided some important insights into this phenomenon, a complete understanding 
of the host/virus interactions that predispose for disease still remains somewhat elusive.    
 This body of research endeavors to provide additional insights into how innate 
and acquired immune mechanisms can shape host responses to RSV infection.  Data 
presented in chapter II and III further support the hypothesis that innate immune 
mechanisms, including TLRs, are important for recognizing RSV and shaping immune 
responses in the lung.  Multiple TLRs including TLR2,3,4,6,and 7, as well as RIG-I, are 
now known to associate with RSV.  These observations underscore the diverse repertoire 
and complexity of signaling utilized by the host innate immune system to control RSV.  
Since multiple innate immune signaling pathways are likely required to promote viral 
clearance and prevent disease, a breakdown in any one pathway may predispose for 
disease.  In fact, evidence supporting this hypothesis has been shown in RSV susceptible 
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infants with TLR4 polymorphisms that blunt innate immune responses (10,174).  Perhaps 
defects in TLR2 signaling may also predispose for disease.  This would be an interesting 
hypothesis to examine. 
 Furthermore, TLR2 signaling influenced DC maturation, suggesting that TLR2 
can directly modulate acquired immune responses.  In fact, studies examining vaccinia 
virus (VV) and TLR2 interactions demonstrated that TLR2/VV interactions could 
influence DC-dependent expansion of T and B cells (178).  This study showed that TLR2 
signals were important for generating anti-VV CD8 T cells and for the functional 
maturation of DCs.  Based on these findings and studies by Rudd et al. showing a role for 
MyD88 responses in RSV disease susceptibility (140), it is tempting to speculate that 
defects in TLR2 signaling could predispose for RSV disease by modulating the DCs 
ability to prime Th1 or Th2 anti-RSV immune responses.   
 Alternatively, RSV itself has been shown to interfere directly with innate immune 
signaling (i.e., TLR3/4-mediated type I IFN production) (144).  Since TLR2 signals are 
important for controlling viral replication, RSV may possess the ability to interfere with 
TLR2-mediated signaling thereby dampening innate immunity.  While evidence 
supporting this hypothesis has not been demonstrated, it has been suggested that the RSV 
SH protein can neutralize TNF-! function (51).  These studies showed rPIV5 expressing 
the RSV SH protein could inhibit TNF-! induced NF-"B expression in an in vitro 
system.  Since data presented here demonstrated TLR2 signals induced strong TNF-! 
responses following RSV interactions, it is likely that RSV has developed mechanisms to 
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counteract at least some of the positive effects of TLR2 signaling.  However, questions 
regarding how RSV might interfere with TLR2 remain unexplored.     
 Furthermore, data presented here clearly demonstrate some type of association  
between TLR2 and RSV, but the ligand for TLR2 on RSV remains undetermined.  
Previous research has demonstrated that RSV surface proteins can interact with TLRs 
(i.e., RSV F and TLR4) (99), suggesting, perhaps, that the RSV G protein, or the RSV 
SH protein, could be potential candidates for this interaction.  The RSV G protein is an 
intriguing candidate, but the protein is difficult to isolate, exists in two different forms, 
and is highly glycosylated, which could mask the antigenic portion of the molecule.  
Therefore, more extensive analysis is needed to determine the ligand for TLR2 on RSV.   
 Of interest, VLPs expressing RSV G protein introduced in chapters IV could 
potentially provide insight into these questions because the G protein is presented on the 
surface of VLPs in its native context and is underglycosylated when grown in avian cells, 
perhaps rendering the G protein more immunogenic than the fully glycosylated form.  
Additionally, the RSV G protein expressed in this vector system could help uncover a 
potential role for the G protein in stimulating innate immunity, through either TLR2 or 
some other innate immune receptor.  Moreover, this expression system could help answer 
some important questions regarding the role of RSV G in stimulating acquired immune 
responses as well.  
 Early studies suggested that RSV G protein did not play a major role in generating 
strong acquired immune responses since neutralizing antibodies are targeted against F 
and not G.  More recent studies have questioned the validity of this hypothesis because 
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the G protein, the soluble form of G in particular, has been shown to down-regulate and, 
perhaps, even directly inhibit some acquired immune responses.  Some studies even 
suggest that soluble G can antagonize the function of anti-RSV neutralizing antibodies by 
serving as an antigen decoy (21).  Furthermore, data presented in Chapter IV argue that 
the G protein can affect the generation of RSV specific CTLs.  However, a defined CD8 
epitope for this protein has not been characterized.  Collectively, these observations 
suggest a more complex role for the RSV G protein than previously recognized.  Perhaps 
a clearer understanding of how the G protein could manipulate both innate and acquired 
immune responses would reveal more clues to the pathogenesis of RSV induced disease.   
 In summary, data presented in chapters II-IV have provided some novel insights 
into the questions surrounding host/RSV interactions that can lead to innate and acquired 
immune responses.    Indeed, RSV pathogenesis is a multi-factorial process likely 
resulting from both host immune responses and cytopathic effects of RSV on lung 
epithelium.  It appears that RSV has successfully managed either to subvert some 
immune pathways through virally encoded proteins or to misdirect immune responses by 
exploiting multiple TLR signaling pathways, perhaps even both.  Therefore, 
understanding how RSV manipulates both innate and acquired responses may be the key 
determinant in understanding the underlying mechanisms of RSV induced pathogenesis.    
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Chapter VI 
Materials and Methods 
 
Chapters II and III 
Animals: 
 Knockout mice were extensively back-bred onto the C57BL/6 background.  
Backcrossing was confirmed by satellite marker analysis (Charles River Laboratories) 
and mice were genotyped by PCR of tail DNA.  Eight to 10 week female TLR1 KO (F9), 
TLR2 KO (F11), TLR4 KO (F11), TLR6 KO (F10), and MyD88 KO (F12) mice (back-
bred from knockout mice originally provided as a gift from Dr. Shizuo Akira) were 
housed under specific pathogen-free conditions at the University of Massachusetts, 
Worcester campus.  Age- and sex-matched C57BL/6, BALB/c, and B6.129F2/J wild-type 
mice were purchased from The Jackson Laboratories.  
 
Growing RSV virus: 
 Human RSV A2 strain was grown in Vero cells.  Briefly, 85-90% confluent T175 
flasks of Vero cells were infected with RSV at 1 MOI in 5 ml of DMEM.  Cells were 
infected for two hours at 37
0
C and 5% CO2.  After infection, 7 ml of DMEM with 10% 
FBS (Gibco), 0.1% Pen/Strep (Cellgro), and 0.001% Cipro (Bayer) was added to the 
flask.  Flasks were incubated for approximately 4 days or until extensive syncytia 
formation was observed.  On the day of harvest, all except 3 ml of supernatant was 
removed and placed on ice in 50 ml conical tubes, approximately 3 ml per tube.  Cells 
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were scraped from the flask, added in equal distribution to conical tubes, and sonicated 
three times, 5 seconds per time, at 25W on ice.  Cell debris was removed by 
centrifugation at 600 g for 7 minutes at 4
0
C.  Virus supernatant was stored in 30% 
sucrose at -80
0
C.  Uninfected flasks were treated identically to generate Vero cell lysate 
control.  
 
Harvesting peritoneal macrophages: 
 Mice were i.p. injected with 4% thioglycollate (Sigma).  Four days after injection 
mice were euthanized and the peritoneum was flushed with normal saline.   
Contaminating red cells were lysed with red blood cell lysing buffer (Sigma) according to 
manufacturer specifications.  The resulting peritoneal exudate cell suspension was 
analyzed by flow cytometry and consisted of > 90% macrophages based on CD11b
+
 
expression (data not shown).  Cells were resuspended in DMEM containing 10% FBS 
(HyClone) and 0.1% Pen/Strep, quantified using a hemocytometer, and added to tissue 
culture plates (Costar) for further analysis.   
 
Macrophage stimulation assays: 
 Peritoneal macrophages were seeded in 96 well round bottom tissue culture 
treated plates (Costar) at 1.0 x 10
6
 cells/ml.  Cells were stimulated with live RSV A2 
strain (0.3 MOI), UV-inactivated RSV A2 strain (0.3 MOI equivalent), TLR4 ligand 
pLPS (100ng/ml)(Sigma), TLR2 ligand Pam2CSK4 (100ng/ml)(Sigma), and Vero cell 
lysate control (50ul/well), as indicated in the text.  UV inactivation of RSV was 
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performed using a UV stratalinker 2400 (Stratagene) at a voltage of 1 x 10
6
 
microjoules/cm
2
.  Inactivation was confirmed by immunoplaque assay.   
 Macrophages were stimulated for 24 hours at 37
0
C and 5% CO2.  After 
stimulation cell supernatants were removed and stored at -20
0
C for ELISA analysis.  
Intracellular TNF-! production was determined using FITC conjugated anti-TNF-
! antibody (BD Pharmingen) and macrophages were gated using PE conjugated anti-
CD11b antibody (BD Pharmingen). 
  
In vivo infection: 
 Mice were lightly anesthetized with isoflurane and intranasally (i.n.) challenged 
with 2.4 x 10
6 
PFU of RSV A2 strain or equal volume of Vero cell lysate control.   
 
Collection and analysis of BAL cells and lung tissue: 
 Mice were anesthetized with isoflurane and exsanguinated by severing the right 
caudal artery.  Bronchoalveolar lavage (BAL) cells were harvested by lavaging the lung 
four consecutive times with 1 ml PBS containing 0.1% BSA.  BAL cells were pooled and 
pelleted by centrifugation at 2000 rpm for 5 minutes. Cells were surface stained with 
FITC conjugated anti-mouse CD11b (clone M1/70, BD Pharmingen), PE conjugated anti-
mouse CD86 (clone GL-1, BD Pharmingen), PE conjugated anti-mouse F4/80 (clone 
BM8, eBioscience) APC conjugated anti-mouse CD11c (clone HL3, BD Pharmingen), 
and/or Alexa-647 conjugated anti-mouse neutrophils (clone 7/4, Serotec). 
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 Lung tissue was removed following BAL harvest.  One half of total lung tissue 
was stored in 30% sucrose for plaque assay.  The remaining half of lung tissue was stored 
in protease inhibitor (Roche) for ELISA analysis.  Tissues were stored at -80
0
C until 
analysis.  For analysis, lungs were thawed on ice and weighed.  Lungs were homogenized 
using a pellet pestle and centrifuged at 2600 g for 10 minutes at 4
0
C to clarify 
supernatant.   
 
RSV immunoplaque assay: 
 Twenty-four well tissue culture plates (Costar) were seeded with 1.5 x 10
5 
Vero 
cells/well in DMEM containing 10% FBS (Gibco), 0.1% Pen/Strep (Cellgro), and 
0.001% ciprofloxacin (Bayer).  Cells were incubated overnight at 37
0
C and 5%CO2.  
Media were removed from confluent monolayers and serial dilutions of RSV stock or 
lung tissue clarified supernatants were absorbed to monolayers.  All samples were run in 
duplicate wells.  Plates were incubated at 37
0
C and 5% CO2 for 2 hours for optimum 
infection.  After incubation, supernatant was removed and 1 ml of M199 media (Gibco) 
containing 0.01% Pen/Strep mixed 1:1 with 2% methylcellulose (Sigma) was overlayed 
on monolayers.  After 6 days of incubation at 37
0
C and 5% CO2, or when extensive 
syncytia developed, overlay was removed and monolayers were fixed with 1 ml of ice-
cold Acetone:Methanol (60:40).  Fixative was removed after 10 minutes and plates were 
air-dried.  Plates were blocked in 5% nonfat dry milk (Biorad) for 10 minutes at room 
temperature.  Primary RSV anti-F and anti-G antibodies (Clone 131-2A, 131-2G, 
Chemicon) were added to wells for two hours followed by secondary HRP anti-mouse Ig 
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antibody (Clone 187.1, BD Pharmingen) for one hour.  Antibodies were diluted in 5% 
milk and plates were incubated at 37
0
C and 5% CO2.  Plates were hand washed twice 
with PBS containing 0.5% Tween 20 (Sigma) after each antibody incubation step.  
Individual plaques were developed using DAB substrate kit (Vector) per manufactures 
specifications.  Limit of detection for our immunoplaque assay is approximately 1.4 log10 
PFU/gram. 
  
ELISA analysis:   
 Clarified lung homogenates and cell supernatants were analyzed for IL-6 (BD 
Pharmingen), TNF-! (BD Pharmingen), CCL2 (MCP-1) (BD Pharmingen), and CCL5 
(RANTES) (R&D Systems) using a sandwich ELISA assay as indicated in the text.  
ELISAs were performed per manufacturer specifications. IFN-$ was measured from cell 
supernatants by ELISA according to the following protocol: monoclonal rat anti-mouse 
IFN-$ (Yamasa Corp., Japan, clone 7F-D3) was used as the capture antibody and 
polyclonal rabbit anti-mouse IFN-$ (PBL Biomedical Laboratories, #32400-1) for 
detection together with HRP-conjugated goat anti-rabbit IgG as the secondary reagent 
(Cell Signaling Technology, Inc. #7074). Mouse IFN-$ (PBL Biomedical Laboratories, 
#12400-1) was used as the standard. 
 
Type I Interferon bioassay: 
 Macrophages were stimulated with RSV A2 (MOI 2), TLR 3 ligand Poly I:C 
(Amersham) (50ug/ml), and TLR4 ligand LPS (100ug/ml) or medium alone for 24 hours.   
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Supernatants were removed and UV-treated to inactivate the infectivity of the virus.  
Serial 2-fold dilutions of UV-inactivated supernatant were added to fresh NTCT929 cells 
at 1 x 10
5
cells/ml in 96 well flat-bottom tissue culture plates (Costar).  Cells were 
incubated for 24 hours at 37
0
C and 5%CO2.  After 24 hours supernatants were removed 
and infected with VSV at 2.5 x 10
3
PFU/ml.  The highest dilution that resulted in a 50% 
reduction of VSV-induced cytopathic effect is defined as 1 U/ml of type one interferon.   
 
Flow cytometric analysis: 
 Harvested cells were washed twice with cold PBS containing 2.0% BSA, 
enumerated using a hemocytometer, and transferred to 96 well round bottom tissue 
culture plates (Costar).  Cells were incubated in anti-mouse CD16/CD32 Fc block (BD 
Pharmingen) for 15 minutes at room temperature.  Cells were washed twice with wash 
buffer and surface stained with indicated antibodies and appropriate isotype controls per 
manufacturers specifications.  Cells were washed twice with wash buffer and 
resuspended in wash buffer for analysis.  For intracellular cytokine staining, cells were 
cultured overnight in the presence of GolgiStop
TM
 (BD Pharmingen).  Following surface 
staining cells were treated with BD Cytofix/Cytoperm
tm 
Plus Kit (BD Pharmingen) per 
manufacturers specifications.  Cells were stained with indicated intracellular antibodies 
and appropriate isotype controls for 30 minutes at 4
0
C in the presence of Perm/Wash 
buffer.  After incubation cells were washed twice with perm/wash buffer and resuspended 
in wash buffer for analysis.  Cells were analyzed using a BD LSR II Flow Cytometer and 
FlowJo 8.4.2 software (TreeStar).   
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Statistical analysis: 
 Statistical significance was determined using an unpaired, two-tailed Student’s t 
test.  Values of p<0.05 were considered significant.  Error bars are +/- SD or +/- SEM as 
indicated in the figure legend.  Statistics were generated using Graph Pad software v4.0c 
(Prism). 
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Chapters IV  
Cells, Virus, Plasmids 
 ELL-0  (avian fibroblasts) were obtained form the American Type Culture 
Collection as were Vero cells, COS-7 cells, and Hep2. ELL-0 cells and Hep2 cells were 
maintained in Eagle’s minimal essential medium (EMEM) (Gibco) supplemented with 
10% fetal calf serum (FCS) and 2 mM glutamine. COS-7 cells were grown in DMEM 
supplemented with nonessential amino acids, vitamins, penicillin, and streptomycin, and 
10% fetal calf serum.   Vero cells were grown in DMEM supplemented with penicillin, 
streptomycin, and 5% fetal calf serum.    RSV, A2 strain, was obtained from Dr. Ralph 
Tripp.   
The RSV G protein cDNA was a codon optimized synthetic gene obtained from 
Novavax, Inc.  NDV NP, M, F and HN protein genes as well as the RSV G protein gene 
were inserted into the pCAGGS expression vector as previously described (107, 108). 
NDV HN protein-RSV G protein chimera gene was constructed by ligation of 
PCR derived DNAs derived from pCAGGS-HN and pCAGGS-G.  Primers used to 
generate a DNA encoding the HN cytoplasmic (CT) and transmembrane (TM) domains 
were GGTTATTGTGCTGTCGACTCATTTTGGC (forward primer) and 
CATACTATATGCCAGGGCGGCCGCAGAGATGGCTAAG (reverse primer).  This 
product was digested with XhoI and Not I (a site introduced without changing the amino 
acid sequence).  The primers used to generate DNA encoding the G protein ectodomain 
were 
CTTCCCTCATCATTGCAGCGGCCGCTCTTGCCTACTCTGCGAATCATAAGGTC 
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(forward primer which introduced a Not I site without changing the amino acid sequence) 
and GCCAGAAGTCAGATGGCCAAGG (reverse primer).  The product was digested 
with Not I and Msc I.  The two DNA fragments were ligated into an XhoI-MscI digested 
pGAGGS vector.  The resulting plasmid containing the chimera protein gene was 
sequenced in its entirety to verify the gene junctions (illustrated in Figure 1, panel A) and 
to ensure that no additional changes were introduced during the PCR reactions.   
  
Antibodies 
Polyclonal rabbit anti-NDV antibody was raised against UV inactivated, purified 
NDV as previously described (109).  Polyclonal goat anti-RSV antibody (Biodesign) and 
mouse monoclonal anti-G antibody (MyBiosource) were used in Western blots.  Anti-
RSV F monoclonal antibody (clone 131-2A, Chemicon) was used in plaque assays.  
Secondary antibodies utilized were anti-goat antibody  (Sigma), anti-mouse antibody 
(Sigma), and anti-rabbit antibody (Sigma). 
 
Transfections   
Transfections were accomplished using Lipofectamine (Invitrogen), as 
recommended by the manufacturer.  For small scale transfections, a mixture of plasmid 
DNA  (0.5µg/35mm plate) and lipofectamine (5!l/35mm plate) in Opti-MEM media 
(Gibco) was incubated at room temperature for 45 minutes, and then added to cells grown 
in 35mm plates and previously washed with OptiMEM. Cells were incubated for 5h at 
37ºC, Opti-MEM was removed, and 2ml of supplemented DMEM were added. 
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For quantitative preparations of VLPs, large-scale transfections of cells growing 
in T-150 flasks were utilized.  For each T-150 flask, plasmid DNA (8µg of each plasmid) 
in 1.6 ml of Opti-Mem and lipofectamine (80 µl ) in 3.2 ml of Opti-MEM were each 
incubated for 15 min at room temperature, mixed, and further incubated for 45 min at 
room temperature.  Opti-Mem (11.2 ml) was mixed with the DNA-lipofectamine 
complexes and added to cells in a T-150 flask that had been twice washed with Opti-
Mem.  Cells and DNA-lipofectamine complexes were incubated for 5 hours at 37 C, the 
complexes removed, and 15 ml of complete media were added.   
 
Polyacrylamide gel electrophoresis, Silver staining, and Western analysis 
Proteins in extracts, virus, or VLPs were resolved on 8% polyacrylamide gels 
(SDS-PAGE) as previously described (127).  Silver staining of proteins in the 
polyacrylamide gels was accomplished as recommended by the manufacturer (Pierce).  
For quantification of individual proteins in the polyacrylamide gels, different 
concentrations of BSA were electrophoresed on the same gel.  A standard curve based on 
the stain of the BSA (using a Biorad densitometer to measure the intensity of staining) 
was used to determine the concentrations of each of the proteins in the purified VLPs or 
virus.  For Western analysis, proteins in the polyacrylamide gels were transferred to 
PVDF membranes (PerkinElmer) using dry transfer (iblot from Invitrogen). Proteins 
were detected in the blots as previously described (91). 
 
VLP purification 
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 At 24 hours post-transfection, heparin was added to the cells at a final 
concentration of 10 µg/ml.  At 72 hours post-transfection and again at 96 hours post-
transfection, cell supernatants were collected and cell debris was removed by 
centrifugation at 5000 rpm (Sorvall GSA SLA-1500 rotor).  VLPs in the supernatant were 
pelleted by centrifugation in a Type 19 Rotor (Beckman) at 18,000 rpm for 12 hours.  
The resulting pellet was resuspended in TNE buffer (25 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, and 5 mM EDTA), dounce homogenized, and layered on top of a discontinuous 
sucrose gradient composed of 2 ml 65% sucrose and 4 ml 20% sucrose. The gradients 
were centrifuged in an SW 28 rotor (Beckman) at 24,000 rpm for 6 hours.  The fluffy 
layer at the 20-65% sucrose interface, containing the VLPs, was collected, mixed with 
two volumes of 80% sucrose, and placed in top of a 1 ml layer of 80% sucrose in a SW41 
Beckman centrifuge tube, and then over layered with 3.5 ml of 50% sucrose and 2ml of 
10% sucrose.  The gradients were centrifuged for 18 hours at 38,000 rpm.  The VLPs, 
which float to the interface of the 50% and 10% sucrose layers, were collected and 
concentrated by centrifugation in an SW50.1 rotor for 16 hours at 38,000 rpm.  All 
sucrose solutions were w/v and dissolved in TNE buffer and all centrifugations were 
done at 4 C.  
 
RSV purification 
 RSV (moi of 0.1) in 5 ml of DMEM without serum was added to confluent Vero 
cells growing in T-150 flasks.  Cells were incubated with virus for 2 hours at 37, and then 
15 ml of DMEM with 5% fetal calf serum were added.  Infected cells were incubated for 
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3-4 days at 37 C.  The cells were then scraped into the cell supernatant; the suspended 
cells were frozen at -80 C, and then thawed.  The resulting cell lysates were clarified by 
centrifugation at 3200 rpm (Sorvall) for 20 minutes.  Virus in the supernatant was 
precipitated using PEG 8000 (50% w/v) added to the supernatant for a final concentration 
of 10% and incubated for 90 min with stirring at 4 C.  The precipitated virus was pelleted 
by centrifugation at 5000 rpm for 20 min at 4 C, snap frozen, and stored at -80 C.  The 
thawed virus pellet was resuspended in 10% sucrose in TNE, homogenized and layered 
on top of a discontinuous sucrose gradient composed of 1 ml of 60%, 3 ml of 45%, and 4 
ml of 30% sucrose (all dissolved in TNE buffer) and the gradient was centrifuged at 
35,000rpm in an SW41 rotor for 90 minutes.  The visible virus band between the 30% 
and 45% sucrose layers was collected.  The viral protein content (M, NP, F, G) of 
purified RSV was determined as described above using known amounts of BSA included 
in the same gel.   
 
RSV UV inactivation 
 Purified virus was diluted in 2 ml of PBS in a 60 mm tissue culture dish and 
placed on a rotating platform 10 cm from a Germicidal Lamp (G15T8, Sylvania) for 20 
minutes, a time previously determined to inactivate 100% of the virus as measured by 
plaque assay.  The efficacy of UV inactivation was determined in a plaque assay. 
 
Formaldehyde treated RSV (FI-RSV) 
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 Formalin inactivated RSV (FI-RSV) was prepared by a modification of the 
method of Prince et al, (135). Virus was harvested from infected Hep-2 cells, clarified by 
centrifugation (1000 x g for 20 min at 4
o
 C), filtered through a 0.8 µ filter, and then 
formalin treated by the addition of 1/10 volume of a 1:400 dilution of 37% formaldehyde 
in water, and incubated for three days at 36
o
 C with gentle stirring.  The formalin-treated 
virus was pelleted at 100,000 x g for 60 min at 10
o
 C and resuspended in 1/20 volume of 
HMEM, 1/10 volume SPG (2 M sucrose, 110 mM potassium phosphate, pH 7.1, 5 mM 
monosodium glutamate).  The resuspended virus was centrifuged at 1000 x g for 15 min 
4
o
C, and the supernatant was incubated with 4 mg/ml Aluminum hydroxide (Alhydrogel) 
overnight at room temperature.  The virus alum mixture was centrifuged at 1000 x g for 
15 min and the Aluminum hydroxide pellet (adsorbed virus) was resuspended in one half 
volume of HMEM, 1/10 volume SPG, and stored in 0.5 ml aliquots at 4
o
C.  The amount 
of virus bound to the alum was estimated at 44% by measuring the amount of total 
protein in the formalin inactivated virus sample before and after alum adsorption.  The 
amount of virus adsorbed to the alum was calculated to be equivalent to 6.1 x 10
8
 pfu/ml.  
This estimate was based on the known virus titer prior to formalin treatment, the volume 
of the virus prior to formalin inactivation; the percent protein bound to the alum, and the 
concentration factors for each step in the procedure.   
 
Antibody neutralization  
Mouse sera were complement inactivated and then diluted in DMEM without 
serum.  Purified RSV virus was diluted to approximately 75 to 150 pfu in 100 µl.  
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Dilutions of mouse sera in 100 µl was added to the virus and incubated for 1 hour at 37
0
 
C.  The mixture was then added to pre-washed, confluent monolayers of Vero cells 
growing in 24 well tissue culture dishes, and the cells were incubated at 37
0
C for one 
hour.  The antibody-virus mixture was removed and 1 ml of methylcellulose overlay was 
added to each well as described above.  Plates were incubated for 3-4 days and plaques 
were stained as described above. 
 
Animal immunization and challenge  
 Mice, 3-week-old BALB/c, from Jackson Laboratories or Taconic laboratories, 
were housed (groups of 5) under pathogen-free conditions in microisolator cages at the 
University of Massachusetts Medical Center animal quarters. All protocols requiring 
open cages were accomplished in biocontainment hoods.  Mice were immunized by 
intraperitoneal (IP) or intramuscular (IM) inoculation of different concentrations of VLPs 
or UV inactivated RSV in 0.5 ml (IP) or 0.05ml (IM) of PBS containing 30% sucrose.  
Other groups of mice were lightly anesthetized with isoflurane and then infected by 
intranasal (IN) inoculation of RSV (1-3 x 10
6
 pfu/mouse in 50 µl). Mice that received an 
immunization boost were injected IP or IM with 10 µg of VLPs or UV RSV/mouse or 1-
3 x 10
6
 pfu/mouse of live RSV (IN). 
 Mice challenged with live RSV were lightly anesthetized as described above and 
infected IN with 1-3 x 10
6
 pfu of virus. 
 
Detection of virus in lung tissue 
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 Mice were anesthetized with isofluorane and exsanguinated after severing the 
right caudal artery.  Lungs were removed aseptically, placed in 0.5 ml of 30% sucrose in 
PBS and stored at -80 C.  Upon thawing, lungs were weighed and then homogenized 
using pestle  (Kontes). The homogenate was centrifuged at 12,000 rpm for 15 min and 
the virus titer in the supernatant was determined by plaque assay as described above. 
 
Determination of antibody titers by ELISA  
Antigens used as targets in ELISA were RSV infected Vero cell extracts, extracts 
from 293T cells transfected with pGAGGS-G, or extracts from COS-7 cells transfected 
with pGAGGS-G. To prepare cell extracts, cell monolayers were washed in cold PBS and 
lysed in TNE buffer
 
(25 mM Tris-HCl pH 7.4, 150 mM NaCl2 and 5 mM EDTA) 
containing 1% Triton
 
X-100.  All antigens were placed in carbonate buffer, pH 9.6, and 
added to microtiter plates (Costar) and incubated overnight at 4
0
C.  Amounts of 
transfected extracts added to each well were adjusted so that the amounts of G protein 
were comparable as determined by Western blot.   
After binding of the target antigen, wells were blocked in 50 µl PBS containing 
1% BSA (bovine serum albumin) at room temperature for 1-2 hours, washed three times 
in PBS, and drained.  Different dilutions of mouse sera were added to the microtiter wells 
in 50 µl of PBS-BSA and incubated for 1 hour at room temperature.  After removing the 
mouse sera and washing wells three times, a biotinylated anti-mouse antibody (1:4000 
dilution)(Sigma) in 50 µl of PBS-BSA was added and the microtiter plates were 
incubated for 1 hour at room temperature.  The microtiter plates were then washed three 
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times in PBS and an HRP conjugated neutravidin (1:4000 dilution) (Pierce) was added in 
50 µl of PBS-BSA (1:4000 dilution).  The microtiter plates were incubated for 1 hour at 
room temperature and washed four times in PBS.  TMB (3,3',5,5',tetramethylbenzidene) 
substrate (Sigma) in 50 µl was added to each well and incubated for 15-20 min.  The 
reaction was stopped with 50 µl 1N H2S04 and the OD was read in a plate reader 
(Molecular Devices). 
 
Cytotoxic T cell assays 
Mice were immunized via a single intramuscular dose of VLP-H/G or infected via 
intranasal instillation with infectious RSV A2, as described above.  Spleens were 
harvested from mice 5 weeks after primary immunization.  Single cell suspensions of 
splenocytes were obtained by passing cells through a 40um nylon cell strainer (BD 
Falcon).  Cells were washed twice with RPMI (Gibco) containing 10% FBS (HyClone) 
and resuspended in RPMI supplemented with 10% FBS, 100u/ml Penn/Strep (Gibco), 
1M HEPES (Gibco), 200mM L-Glutamine (Gibco), and 55mM 2-mercaptoethanol 
(Gibco) (assay medium).   
 For in vitro restimulation, single cell suspensions of naïve splenocytes harvested 
from unimmunized mice were generated as described above. Contaminating red blood 
cells were lysed using RBC lysis buffer (Sigma) and washed twice with assay medium. 
For use as the stimulator population, splenocytes infected for 18 hours with infectious 
RSV A2 (MOI 10) were irradiated with 3000 rad of 
251
Cesium.  Stimulators were washed 
twice with RPMI (Gibco) containing 10% FBS, resuspended in assay medium and then 
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mixed with primed splenocytes in a 5:1 ratio in 2ml of assay medium per one well of a 24 
well tissue culture treated polystyrene plate (Costar).  Cells were cultured at 37
0
C and 5% 
CO2 for 5 days.  After 5 days, splenocytes were harvested, washed 2 times with RPMI 
containing 10% FBS and resuspended in MEM (Gibco) containing 5% FBS.  
 Splenic CD8 T cell function was enumerated using a classical 
51
chromium release 
assay.  Briefly, P815 (H-2d) mastocytoma target cells were cultured in DMEM (Gibco) 
supplemented with 10% FBS, 100u/ml Penn/Strep, 1M HEPES, 200mM L-Glutamine, 
and 55mM 2-mercaptoethanol.  P815 cells were infected with RSV A2 (MOI=10) for 
18hrs then washed two times with DMEM containing 10% FBS and counted using a 
hemocytometer.  2 x 10
6
 cells were incubated with 500 µCi of 
51
Cr for 1 hour then 
washed 3 times with DMEM containing 10% FBS.  Cells were resuspended in MEM 
containing 5% FBS and incubated with in vitro restimulated effector splenocytes at 
indicated effector:target ratios in 200ul total volume. 1 x 10
4
 target cells were added in 
triplicate to 96 well U-bottom tissue culture plates for each condition. After 4 hours of 
incubation, plates were centrifuged at 400 X g for 5 minutes and 50µl of cell supernatant 
was added to 150µl of optiphase supermix (Wallac).  Samples were enumerated using a 
beta-counter (Wallac). 
51
Cr labeled target cells were incubated with 5% Triton-X 100 or 
medium along to measure maximum and spontaneous release.  Percent specific lysis for 
each well was calculated as: (experimental release-spontaneous release)/(maximum 
release-spontaneous release) X 100. 
 
Pulmonary histology of RSV infected mice 
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 For histological analysis of lung tissue, mice were anesthetized with isofluorane 
and exsanguinated after severing the right caudal artery.  The lungs were then fixed via 
infusion through the trachea with 4% formalin, removed, and immersed in 4% formalin 
for 24 hours, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H 
and E) or periodic acid Schiff (PAS) by the University of Massachusetts Core Facility.  
Six sections per mouse were obtained.  Sections from each mouse were scored, blindly, 
for the degree of inflammation (H and E stains) of blood vessels, airways, or interstitial 
spaces on a scale of 0 to 3 as previously described (114).  For sections stained with PAS, 
the percents of airways positive for PAS in 25 randomly selected airways were 
determined.  
 
Statistical analysis: 
 Statistical significance was determined using an unpaired, two-tailed Student’s t 
test.  Values of p<0.05 were considered significant.  Error bars are +/- SD or +/- SEM as 
indicated in the figure legend.  Statistics were generated using Graph Pad software v4.0c 
(Prism). 
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Appendix I: 
 
 The data presented in this publication was conducted in the laboratory of Dr. 
Michael Clare-Salzler during my tenure as a graduate student at the University of Florida.  
My contributions to this publication were; performed all FACS analysis, isolated PBMC, 
purified Treg, presented data as an oral presentation at the 8th Immunology of Diabetes 
Society, Hyogo, Japan, wrote manuscript.  Dr. Abdoreza Davoodi-Semiromi performed 
western blotting analysis.  
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ABSTRACT 
 
Abstract:  Regulatory T cells (Treg), characterized as CD4+/CD25+hi T cells, are critical 
for sustaining and promoting immune tolerance. Treg are highly dependent on IL-2 and 
IL-2 signaling to maintain their numbers and function and interruption of this pathway 
promotes autoimmunity. The transcription factor, Foxp3, is also required for Treg 
function as defective Foxp3 promotos autoimmunity in both mice and humans. We 
previously reported a point mutation in the DNA-binding domain of the NOD STAT5B 
gene that limits DNA binding when compared to wild-type STAT5 mice. Based on the 
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presence of five STAT5B consensus sequences in the Foxp3 promotor, we hypothesized 
a critical linkage between IL-2 signaling/STAT5B and Foxp3 expression in Treg. Our 
data show IL-2 activates long-form (LF) STAT5 and sustains Foxp3 expression in Treg. 
In contrast, CD4+/CD25- T cells do not active LF STAT5 and do not express Foxp3 
under the same conditions. In addition, blocking LF STAT5 activation with a Jak 
inhibitor (AG-490) significantly reduced Foxp3 expression in Treg. Examination of 
human Treg using flow cytometry and intracellular staining for Foxp3 expression 
likewise demonstrates that IL-2 maintains Foxp3 expression through LF STAT5 
signaling. These studies reveal a critical link between IL-2 mediated JAK-STAT5 
signaling and the maintenance of Foxp3 expression in Treg of mice and humans. 
DIGITAL OBJECT IDENTIFIER (DOI) 
10.1196/annals.1375.031 About DOI 
  
  
  
INTRODUCTION 
 
Natural regulatory T cells (Treg) (CD4+/CD25+hi) are generated in both the thymus and 
the periphery and are essential for the promotion of immune tolerance while preventing 
the onset of autoimmune disease.1–3 Treg express the alpha chain of interleukin (IL)-2 
receptor (CD25) and are vitally dependent on exogenous IL-2 secreted from naïve and 
effector T cells (Teff) for maintenance in the periphery.4 This notion is supported by 
experiments that demonstrate depletion of IL-2 (IL-2KO) or the IL-2 receptor-signaling 
pathway (IL2"-/-, IL-2#-/-) ablates Treg in mice and leads to the development of 
autoimmune disease.5 Treatment of these mice with IL-2 restores Treg number and 
function.5 It is also known that the transcription factor, Foxp3, is critical for suppressor 
activity of Treg because mice lacking Foxp3 succumb to severe lymphoproliferative and 
autoimmune disease.6 Interestingly, Van Parijs and colleagues reported that STAT5 KO 
mice exhibited a loss of Treg and over expression of STAT5 in IL-2 KO mice restores 
Treg numbers in vivo.7 These findings demonstrate that Jak/STAT5 signaling is an 
essential component of murine Treg. We recently reported a novel point mutation in the 
DNA-binding domain in the STAT5B gene in NOD mice and demonstrated that mutated 
STAT5B has a weaker DNA-binding affinity when compared with normal C57BL/J6 
mice.8 We hypothesize that this mutation may affect the maintenance of Foxp3 in murine 
Treg. Our data show the Jak/STAT5-signaling pathway is utilized to maintain Foxp3 
expression and blockage of this pathway completely inhibited activation of STAT5 while 
significantly reducing Foxp3 expression in both mouse and human natural Treg. 
  
  
MATERIALS AND METHODS 
  
Mice 
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C57BL/6J (B6) mice were purchased from Jackson Laboratories and housed in our 
mouse colony facilities in the Department of Pathology, Immunology, and Laboratory 
Medicine, University of Florida. All mice used in these experiments were maintained in a 
specific pathogen-free environment and in accordance with the University of Florida 
institutional animal care and use committee (IACUC). All experiments were conducted 
on 4- to 6-week-old female mice. 
  
  
Treg Purification 
Murine CD4+/CD25+ T cells were purified from the spleens of three mice. Cell 
suspensions were made by passing tissue through a metal mesh grid followed by a 
passage through a 70-µM cell strainer (BD Biosciences, Bedford, MA). The cells were 
pelleted, resuspended in 30 mL of RPMI-1640, counted using a hemocytometer, and 
assessed for viability (viability >95% as judged by Trypan Blue staining). The 
CD4+/CD25+ T cells were separated using mouse CD4+/CD25+ Treg cell purification 
kit (Miltenyi Biotech, Auburn, CA) with an AutoMACS instrument according to 
manufacture's instructions (Miltenyi Biotech). 
  
  
Cell Culture 
 
The purified CD4+/CD25+ Treg were cultured in RPMI-1640 plus 10% FBS (Mediatech, 
Inc., Herndon, VA) and PSN antibiotics (Invitrogen Co., Carlsbad, CA). For Western 
blotting, at the end of culture, cells were washed twice in cold PBS, pelleted, and kept 
frozen at -80°C until analysis. 
  
  
Western Blotting 
 
A total number of 2.0 $ 105 CD4+/CD25+ T cells were cultured in the presence or 
absence of cytokines and inhibitor and then lysed in Laemmli sample buffer (Biorad 
Laboratories, Hercules, CA). The protein was denatured for 5 min in boiling water and 
loaded onto a 10% Tris-HCl acrylamide gel (Biorad) followed by a 1 h transfer to 
polyvinylidene fluoride (PVFD) membrane (Amersham Biosciences Corp., Piscataway, 
NJ). Tyrosine-phosphorylated STAT5 was detected using anti-STAT5A/B antibody (Cat 
#05-495, Upstate) and pan-STAT5A/B antibody (Cat #SC-835 and #SC-836, Santa Cruz 
Biotech, Santa Cruz, CA). Mouse IL-2 (Cat #1271164, Roche Applied Sciences, 
Indianapolis, IN) was used to stimulate T cells at a concentration range of 5–100 U/mL. 
Anti-mouse Foxp3 antisera was a generous gift from Dr. Alexander Rudensky 
(Department of Medicine, Division of Rheumatology, University of Washington, Seattle, 
WA). AG490 (Calbiochem, La Jolla, CA) was preincubated with cell cultures for 30 min 
prior to lysis at 100 µM (lane 6–7) concentration. 
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PBMC Isolation 
 
Whole blood was collected from healthy controls under Institutional Review Board (IRB) 
approval in our lab using venupuncture. Peripheral blood mononuclear cells (PBMC) 
were isolated from whole blood using Ficoll Paque (Amersham Biosciences Corp., 
Piscataway, NJ, USA) according to manufacturer protocol. PBMC were stained with anti-
CD4 and anti-CD25 antibodies (BD Biosciences) in PBS with 2% FBS and sodium azide. 
After surface staining, cells were intracellular stained for Foxp3 using anti-Foxp3 
monoclonal antibody (E-biosciences, clone #PCH101, San Diego, CA) according to 
manufacturer protocol. Cells were analyzed using four-color cytometric analysis 
(FacsCaliber™, BD Biosciences). Appropriate isotype controls were included for all 
antibodies. PBMC were cultured for 24 h in RPMI-1640 plus glutamine (Mediatech, Inc.) 
and PSN antibiotics (Invitrogen Co.). A 2% autologous serum was added at the beginning 
of culture. AG-490 was diluted in DMSO as per manufacturer specifications and added to 
cultures 30 min prior to IL-2 stimulation. A DMSO control was included and did not 
affect results (data not shown). 
  
  
RESULTS 
 
Table 1 shows the position of the STAT5 consensus-binding sequences located within the 
first three kilobases of the murine Foxp3 promotor region. Each site has been tested for 
binding activity using electromobility gel shift assays and all were found to be active in 
binding STAT5 in Treg (data not shown). In agreement with our previous observations, 
mutated STAT5B in NOD Treg had a threefold weaker DNA binding when compared 
with normal B6 Treg (ADS and MCS manuscript in preparation). This suggests IL-
2/STAT5 signaling may directly regulate Foxp3 expression in Treg. 
  
TABLE 1. The murine Foxp3 promotor contains five STAT5B consensus binding 
sequences: 
 
Position Consensus sequence  Strand 
810–828 tttcgTTCcgaGAAgtggc  Negative 
1007–1025 actgtTTCttaGAAgctgt  Negative 
1124–1142 cctctTTCtgaGAAtgtac  Positive 
1530–1548 cacggTTCtagGAAgccag  Positive 
1717–1735 gtagcTTCtgaGAAcagcc  Negative 
 
Note: A 3-kb region of the Foxp3 promotor from the initiation of the translation codon 
(ATG) was searched for the presence of STAT5B consensus sequences using Genomatics 
software (http://www.genomatix.de). The positions are listed and the conserved binding 
domain, TTC(N)3GAA, in the genomic DNA is shown for each position. Negative 
Strand = antisense strand; Positive strand = sense strand. 
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In Figure 1 A, we tested the hypothesis that IL-2/STAT5 signaling is important to 
maintain Foxp3 expression in murine Treg. In lane 1, freshly isolated Treg express Foxp3 
and lack phosphorylated STAT5. In the absence of IL-2 for 24 h, Foxp3 expression is 
lost, suggesting that IL-2 is required for the maintenance of this transcription factor (lane 
2). Culturing Treg in the presence of IL-2 not only maintains expression of Foxp3 but 
also promotes phosphorylation of LF-STAT5 (lane 3). In lanes 3–5, we demonstrate that 
increasing concentrations of IL-2 sustains Foxp3 expression and activates STAT5. 
However, culturing Treg in the presence of a selective Jak2/3 inhibitor (AG-490) and IL-
2 abrogates STAT5 activation and substantially diminished the expression of Foxp3 in 
Treg (Fig. 1 A, lanes 6–7). We observed similar results in human Treg. As shown in 
Figure 1 B, freshly isolated human Treg express Foxp3 (dark gray histogram). In Figure 1 
C, Foxp3 expression is upregulated by IL-2 stimulation (1000 U/mL) after 24 h, (dark 
gray histogram) and downregulated with the addition of AG-490 (100 µM) (light gray 
histogram). The isotype control for Foxp3 is shown in black for both histograms. Figure 1 
D shows the statistical significance among groups (P= 0.002) using the ANOVA repeated 
measures (n= 3). Post hoc t-tests were used to assess significance between the groups 
(**= 0.001, ***= 0.0001). 
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FIGURE 1.  (A) Murine regulatory T cells were examined via Western blot for 
expression of Foxp3 and FL-pSTAT5. Lane 1: freshly isolated cells without IL-2. Lane 2: 
cultured Treg without IL-2. Lanes 3–5: cultured Treg with different concentrations of IL-
2 ranging from 5 to 100 U/mL. Lanes 6 and 7: Treg cultured with AG-490 (100 µM) in 
the presence of IL-2 (100 U/mL). This represents one of at least three independent 
experiments. (B) Human TREG were examined via flow cytometry for expression of 
Foxp3 using a PE-labeled monoclonal antibody. The isotype is shown in black and Foxp3 
expression of freshly isolated Treg is shown in dark gray. This represents one of three 
independent experiments. (C) Human TREG examined via flow cytometry for expression 
of Foxp3 after 24 h in culture. The isotype is shown in black. Foxp3 expression after 24 h 
of IL-2 (1000 U/mL) stimulation is shown in dark gray. Foxp3 expression after 24 h of 
IL-2 (1000 U/mL) stimulation and AG-490 pretreatment (100 µM) is shown in light gray. 
This represents one of three independent experiments (D) Statistical significance of mean 
fluorescence intensity from B and C above. Error bars represent ± SD. 
  
  
DISCUSSION 
 
In this study, we attempt to identify how the IL-2 signaling pathway contributes to the 
maintenance of natural Treg. IL-2 has been shown to initiate a multitude of cellular 
events, specifically, augmentation and suppression of cytokine secretion by T 
lymphocytes and proliferation of naïve T cells.9 Recently, two independent studies 
demonstrate IL-2 is not directly required for Treg function, differentiation, or expansion 
of suppressor Treg in the thymus, but is required for the survival of mature Foxp3+ 
Treg.10,11 Our data support these findings and suggest that IL-2 signaling maintains 
Foxp3 expression in both murine and human Treg through the Jak/STAT5 pathway. We 
also demonstrate that blockade of the Jak/STAT5 pathway via AG-490, which selectively 
blocks Jak2/3, abrogates STAT5 activation and severely diminished Foxp3 expression. 
Thus, IL-2 binding to the high-affinity IL-2 receptor CD25 initiates a signaling cascade 
by which Foxp3 is maintained in Treg. Without IL-2, this signaling pathway is not 
activated and Foxp3 expression is lost, perhaps altering the suppressive capabilities of 
both murine and human Treg. We theorize that CD25 expression maintains Treg function 
even in environments of low IL-2 concentration, for example, immune homeostasis. 
Thus, Treg maintain Foxp3 in response to a wide spectrum of IL-2 concentrations, 
promoting suppression, and limiting the ability of Teff to proliferate in response to IL-2. 
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